

Committee for Risk Assessment
RAC

Annex 1
Background document
to the Opinion proposing harmonised classification
and labelling at EU level of

benzyl(diethylamino)diphenylphosphonium
4-[1,1,1,3,3,3-hexafluoro-2-(4-
hydroxyphenyl)propan-2-yl]phenolate

EC Number: 479-100-5
CAS Number: 577705-90-9

CLH-O-0000006967-56-01/F

The background document is a compilation of information considered relevant by the dossier submitter or by RAC for the proposed classification. It includes the proposal of the dossier submitter and the conclusion of RAC. It is based on the official CLH report submitted to public consultation. RAC has not changed the text of this CLH report but inserted text which is specifically marked as 'RAC evaluation'. Only the RAC text reflects the view of RAC.

Adopted
18 March 2021

CLH report

Proposal for Harmonised Classification and Labelling

**Based on Regulation (EC) No 1272/2008 (CLP Regulation),
Annex VI, Part 2**

International Chemical Identification:

**Benzyl(diethylamino)diphenylphosphonium
hydroxyphenyl)propan-2-yl]phenolate**

4-[1,1,1,3,3,3-hexafluoro-2-(4-

EC Number: 479-100-5

CAS Number: 577705-90-9

Index Number: -

Contact details for dossier submitter:

Swedish Chemicals Agency

Esplanaden 3A, P.O Box 2

SE-172 13 Sundbyberg, Sweden

kemi@kemi.se

+46 8 519 41 100

Version number: 2

Date: 16/12/2019

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

CONTENTS


1	IDENTITY OF THE SUBSTANCE	1
1.1	NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE.....	1
1.2	COMPOSITION OF THE SUBSTANCE	2
2	PROPOSED HARMONISED CLASSIFICATION AND LABELLING	3
2.1	PROPOSED HARMONISED CLASSIFICATION AND LABELLING ACCORDING TO THE CLP CRITERIA	3
3	HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING	5
4	JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL	6
5	IDENTIFIED USES	6
6	DATA SOURCES	6
7	PHYSICOCHEMICAL PROPERTIES	7
8	EVALUATION OF PHYSICAL HAZARDS	8
9	TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)	8
9.1	SHORT SUMMARY AND OVERALL RELEVANCE OF THE PROVIDED TOXICOKINETIC INFORMATION ON THE PROPOSED CLASSIFICATION.....	10
10	EVALUATION OF HEALTH HAZARDS	11
10.1	ACUTE TOXICITY ORAL ROUTE	11
10.2	ACUTE TOXICITY DERMAL ROUTE.....	11
10.3	ACUTE TOXICITY INHALATION ROUTE	11
10.4	SKIN CORROSION/IRRITATION	11
10.5	SERIOUS EYE DAMAGE/EYE IRRITATION	11
10.6	RESPIRATORY SENSITISATION.....	11
10.7	SKIN SENSITISATION	11
10.8	GERM CELL MUTAGENICITY	11
10.9	CARCINOGENICITY	12
10.10	REPRODUCTIVE TOXICITY.....	12
10.10.1	<i>Adverse effects on sexual function and fertility (data on BPAF)</i>	12
10.10.2	<i>Short summary and overall relevance of the provided information on adverse effects on sexual function and fertility</i>	16
10.10.3	<i>Comparison with the CLP criteria</i>	26
10.10.4	<i>Adverse effects on development</i>	27
10.10.5	<i>Short summary and overall relevance of the provided information on adverse effects on development</i> 29	29
10.10.6	<i>Comparison with the CLP criteria</i>	32
10.10.7	<i>Adverse effects on or via lactation</i>	33
10.10.7	<i>Short summary and overall relevance of the provided information on effects on or via lactation</i>	34
10.10.8	<i>Comparison with the CLP criteria</i>	34
10.10.9	<i>Conclusion on classification and labelling for reproductive toxicity</i>	35
10.11	SPECIFIC TARGET ORGAN TOXICITY-SINGLE EXPOSURE	53
10.12	SPECIFIC TARGET ORGAN TOXICITY-REPEATED EXPOSURE	54
10.13	ASPIRATION HAZARD.....	54
11	EVALUATION OF ENVIRONMENTAL HAZARDS	54
12	EVALUATION OF ADDITIONAL HAZARDS	54
13	ADDITIONAL LABELLING	54
14	REFERENCES	54

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

1 IDENTITY OF THE SUBSTANCE

1.1 Name and other identifiers of the substance

Table 1: Substance identity and information related to molecular and structural formula of the substance

Name(s) in the IUPAC nomenclature or other international chemical name(s)	benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate
Other names (usual name, trade name, abbreviation)	benzyl(diethylamino)diphenylphosphanium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]benzen-1-olate Adduct Quaternary Phosphonium salt/BAF 1/1 XA11 System
ISO common name (if available and appropriate)	n.a.
EC number (if available and appropriate)	479-100-5
EC name (if available and appropriate)	-
CAS number (if available)	577705-90-9
Other identity code (if available)	n.a.
Molecular formula	C38H36F6O2NP
Structural formula	 <p>The structural formula section contains two chemical structures. On the left is the benzyl(diethylamino)diphenylphosphonium cation, showing a central phosphorus atom (P+) bonded to three phenyl rings and a diethylamino group (-N(CH2CH3)2). On the right is the 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate anion, showing a central carbon atom bonded to a benzyl group, a 4-hydroxyphenyl group, and two trifluoromethyl groups (-CF3). The phenolate part is shown as a benzene ring with an oxygen atom at the para position relative to the central carbon.</p>
SMILES notation (if available)	n.a.
Molecular weight or molecular weight range	n.a.
Information on optical activity and typical ratio of (stereo) isomers (if applicable and appropriate)	n.a.
Description of the manufacturing process and identity of the source (for UVCB substances only)	n.a.
Degree of purity (%) (if relevant for the entry in Annex VI)	n.a.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

1.2 Composition of the substance

Table 2: Constituents (non-confidential information)

Constituent (Name and numerical identifier)	Concentration range (% w/w minimum and maximum in multi-constituent substances)	Current CLH in Annex VI Table 3.1 (CLP)	Current self-classification and labelling (CLP)
Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate EC no. 479-100-5	≥ 88% - ≤ 94%	None	Acute Tox .4 , H302 Eye Irrit. 2, H319

Table 3: Impurities (non-confidential information) if relevant for the classification of the substance

Impurity (Name and numerical identifier)	Concentration range (% w/w minimum and maximum)	Current CLH in Annex VI Table 3.1 (CLP)	Current self-classification and labelling (CLP)	The impurity contributes to the classification and labelling
-				

Table 4: Additives (non-confidential information) if relevant for the classification of the substance

Additive (Name and numerical identifier)	Function	Concentration range (% w/w minimum and maximum)	Current CLH in Annex VI Table 3.1 (CLP)	Current self-classification and labelling (CLP)	The additive contributes to the classification and labelling
-					

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

2 PROPOSED HARMONISED CLASSIFICATION AND LABELLING

2.1 Proposed harmonised classification and labelling according to the CLP criteria

Table 5: Proposed harmonised classification and labelling according to the CLP criteria.

	Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	No current Annex VI entry										
Dossier submitter's proposal		benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate	479-100-5		Repr. 1B	H360F	GHS08 Dgr	H360F			
Resulting Annex VI entry if agreed by RAC and COM		benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate	479-100-5		Repr. 1B	H360F	GHS08 Dgr	H360F			

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Table 6: Reason for not proposing harmonised classification and status under public consultation

Hazard class	Reason for no classification	Within the scope of public consultation
Explosives	hazard class not assessed in this dossier	No
Flammable gases (including chemically unstable gases)	hazard class not assessed in this dossier	No
Oxidising gases	hazard class not assessed in this dossier	No
Gases under pressure	hazard class not assessed in this dossier	No
Flammable liquids	hazard class not assessed in this dossier	No
Flammable solids	hazard class not assessed in this dossier	No
Self-reactive substances	hazard class not assessed in this dossier	No
Pyrophoric liquids	hazard class not assessed in this dossier	No
Pyrophoric solids	hazard class not assessed in this dossier	No
Self-heating substances	hazard class not assessed in this dossier	No
Substances which in contact with water emit flammable gases	hazard class not assessed in this dossier	No
Oxidising liquids	hazard class not assessed in this dossier	No
Oxidising solids	hazard class not assessed in this dossier	No
Organic peroxides	hazard class not assessed in this dossier	No
Corrosive to metals	hazard class not assessed in this dossier	No
Acute toxicity via oral route	hazard class not assessed in this dossier	No
Acute toxicity via dermal route	hazard class not assessed in this dossier	No
Acute toxicity via inhalation route	hazard class not assessed in this dossier	No
Skin corrosion/irritation	hazard class not assessed in this dossier	No
Serious eye damage/eye irritation	hazard class not assessed in this dossier	No
Respiratory sensitisation	hazard class not assessed in this dossier	No
Skin sensitisation	hazard class not assessed in this dossier	No
Germ cell mutagenicity	hazard class not assessed in this dossier	No
Carcinogenicity	hazard class not assessed in this dossier	No
Reproductive toxicity	harmonised classification proposed	Yes
Specific target organ toxicity-single exposure	hazard class not assessed in this dossier	No
Specific target organ toxicity-repeated exposure	hazard class not assessed in this dossier	No
Aspiration hazard	hazard class not assessed in this dossier	No
Hazardous to the aquatic environment	hazard class not assessed in this dossier	No
Hazardous to the ozone layer	hazard class not assessed in this dossier	No

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

3 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING

No previous harmonised classification and labelling.


RAC general comment

Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (from here on called BDDP-BPAF) is registered under REACH with a tonnage band of 1–10 t/a. Tonnage data from another individual registrant of a NONS substance is claimed as confidential and according to the ECHA website manufacture was ceased in 2019.

The substance BDDP-BPAF is a salt of the bisphenol AF (BPAF; EC No. 216-036-7)-based anion moiety, and a quaternary phosphonium cation, i.e. the Benzyl(diethylamino)diphenylphosphonium (BDDP) cation. The substance thus contains two components, each at ca. 50%.

The substance is used in the fluoropolymers manufacturing. The sector of end use is manufacturing of rubber and plastic products.

The substance has the following chemical structure:



BDDP-BPAF has currently no harmonised classification. It is self-classified as:

Eye Irrit. 2; H319

Acute Tox. 4; H302

Aquatic Chronic 2; H411

The dossier submitter (DS) restricted the current CLH proposal to adverse effects on sexual function and fertility, for which classification in Category 1B was proposed, as well as adverse effects on development of the offspring and adverse effects on or via lactation, for which no classification was proposed.

The DS proposed read across from BPAF to this substance. Bisphenol AF is an organofluorine compound and derivative of bisphenol A (BPA) having the methyl hydrogens replaced by fluorines. RAC agrees with the DS that the CLH proposal under

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

consideration can be assessed based on data for BPAF.

BDDP-BPAF is an ionic organic compound expected to quickly dissociate in water and biological fluids to BPAF and BDDP. Due to the dissociation behaviour, the substance toxicity can be assessed based on its two dissociation products. Bisphenol AF can be used as the source substance to read across to BDDP-BPAF, because the CLH proposal under consideration, Repr. 1B; H360F, is based on the data on the BPAF component. The organism will be exposed to the common compound BPAF, and the properties of the target substance are predicted to be quantitatively equal to that of the source substance BPAF. No data has been made available in the CLH report on the BDDP component of the substance and the prediction of the toxic properties is based on data on BPAF only.

Bisphenol AF, which is contained in the salt BDDP-BPAF at a concentration of approximately 50%, is a structural analogue and functionally similar to BPA. In 2014, BPA was classified as Repr. 1B; H360F by RAC (ECHA, 2014). In December 2020, RAC classified another analogue, bisphenol S (BPS), as Repr. 1B (H360FD) based on similar toxicological properties. Despite the structural and functional similarities between the substances, the classification proposal for BPAF, and thus BDDP-BPAF, is based on data for the substance itself. The similarity of the hazard profile to BPA and BPS has been acknowledged in this opinion under "Further considerations".

4 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL

There is no requirement for justification that action is needed at Community level. Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate has CMR properties (reproductive toxicity). Harmonised classification and labelling for CMR and respiratory sensitisation is a community-wide action under Article 36 of the CLP regulation.

Data on bisphenol AF (BPAF) is used as the basis for this CLH proposal. Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate is a 1:1 salts of a BPAF-based anion moiety, and a cation. The substance thus contains ca 50% BPAF.

5 IDENTIFIED USES

The substance is used in the fluoropolymers manufacturing. The sector of end use is manufacturing of rubber and plastic products. There is currently no active registrations under REACH.

6 DATA SOURCES

- Data on the substance in the publically disseminated REACH registration dossier (ECHA dissemination, 2019)
- Data available on BPAF, both from searches in PubMed open literature and by access to the full study report of the combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD TG 422; Study report, 2011) that was given from the registrant of BPAF.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

7 PHYSICOCHEMICAL PROPERTIES

Table 7: Summary of physicochemical properties

Property	Value	Reference	Comment (e.g. measured or estimated)
Physical state at 20°C and 101,3 kPa	Solid (white powder)	REACH registration (ECHA dissemination, 2019)	Visual determination
Melting/freezing point	70 - 120 °C	REACH registration (ECHA dissemination, 2019)	Measured
Boiling point	-	REACH registration (ECHA dissemination, 2019)	Data waiving: study scientifically not necessary
Relative density	1.32 g/cm ³	REACH registration (ECHA dissemination, 2019)	Measured
Vapour pressure	0 mm Hg at 25 °C	REACH registration (ECHA dissemination, 2019)	Estimated (Modelling was conducted assuming a covalent structure for the ion pair)
Surface tension	58.5 mN/m	REACH registration (ECHA dissemination, 2019)	Measured.
Water solubility	1.31 g/L	REACH registration (ECHA dissemination, 2019)	Measured.
Partition coefficient n-octanol/water	At 22 °C: 0.9	REACH registration (ECHA dissemination, 2019)	Measured
Flash point	-	REACH registration (ECHA dissemination, 2019)	Data waiving: study technically not feasible
Flammability	Not flammable	REACH registration (ECHA dissemination, 2019)	Measured
Explosive properties	Non explosive	REACH registration (ECHA dissemination, 2019)	Measured
Self-ignition temperature	-	REACH registration (ECHA dissemination, 2019)	Data waiving: study scientifically not necessary

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Property	Value	Reference	Comment (e.g. measured or estimated)
		2019)	
Oxidising properties	-	REACH registration (ECHA dissemination, 2019)	Data waiving: study scientifically not necessary
Granulometry	D10: 38 µm D50 397 µm D90 771 µm	REACH registration (ECHA dissemination, 2019)	Measured
Stability in organic solvents and identity of relevant degradation products	-		Not relevant
Dissociation constant	-		Not relevant
Viscosity	-		Not relevant

8 EVALUATION OF PHYSICAL HAZARDS

Not evaluated in this CLH proposal.

9 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)

Data on BPAF is used as the basis for this CLH proposal. Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate is a 1:1 salts of a BPAF-based anion moiety, and a cation. The substance thus contains ca 50% BPAF.

Table 8: Summary table of toxicokinetic studies

Method	Results	Remarks	Reference
Test substance: BPAF Non-test guideline, in vivo experimental study. Disposition of BPAF was studied in male and female Harlan Sprague-Dawley rats and B6C3F1/N mice following oral administration to C14-labelled BPAF (97% purity) at doses of 3.4, 34 or 340 mg/kg (4 animals per group). A dose of 34 mg/kg was also given intravenously (to 4 animals per group except for male mice: N=3).	Rats: BPAF was well absorbed and excreted mainly in the feces after oral administration. Female rats excreted more BPAF in urine compared to male rats. Total residual radioactivity in tissues was low (72 h after substance administration). The concentration in liver was higher than in other organs (except for GI tract). In male rats, 52% of a 340 mg/kg oral dose was excreted in bile (24 h), which mostly included BPAF		Waidyanatha et al. 2015.

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

Method	Results	Remarks	Reference
<p>Urine and feces were collected at 8 (urine only) and 24 h, and 24-h intervals throughout the study. Blood, bile and tissue samples (skin, muscle, adipose, bladder, spleen, heart, pancreas, liver, kidney, brain, lung, thyroid, ovaries, uterus, testes, small intestine, large intestine, cecum and stomach) were collected.</p>	<p>glucuronide.</p> <p>Mice: As in rats, BPAF was excreted mainly in the feces after oral administration. Female mice excreted more BPAF in urine compared to males.</p> <p>Highest tissue BPAF levels were found in gall bladder.</p>		
<p>Test substance: BPAF</p> <p>Non-test guideline, in vivo experimental study.</p> <p>Toxicokinetics and bioavailability of BPAF (>99% purity) was studied in Harlan Sprague Dawley rats and B6C3F1/N mice of both sexes. No information was found on the number of animals used.</p> <p>Single oral doses at 34, 110 and 340 mg/kg were given to rats and a dose of 34 mg/kg was given to mice. In addition, a dose of 34 mg/kg was given intravenously (IV) to both rats and mice.</p> <p>Blood samples were collected at target times 0, 5, 15, 30 min, 1, 2, 4, 8, 12, 24, 32 and 48 h.</p>	<p>Rats: BPAF was detected at all time points in plasma of both males and females after oral administration. BPAF was rapidly absorbed.</p> <p>The bioavailability was low. Total BPAF was higher than free BPAF, indicating rapid and extensive conjugation. Total BPAF was rapidly eliminated with half-lives ranging from 2.60 to 4.61 h (depending on dose) after oral administration, except for high dose females for which the elimination half-life was 20.2 h. Free BPAF was cleared more rapidly than total BPAF.</p> <p>Mice: BPAF was absorbed rapidly after oral administration. The substance was cleared rapidly, with elimination half-lives of 4.22 h for males and 1.33 h for females (free BPAF). Conjugation was rapid and extensive. Total BPAF was cleared from plasma with an elimination half-life of 0.753 h and 0.804 h for males and females, respectively.</p> <p>No sex differences were seen. In both rats and mice BPAF was rapidly and extensively conjugated following oral administration. The bioavailability was low in both species, though slightly higher in mice than in rats (3-6% vs. 1%).</p>		Waidyanatha et al. 2019.
<p>Test substance: BPAF</p> <p>Non-test guideline, in vivo experimental study.</p> <p>BPAF (98% purity) 10 mg/kg was given orally to 4 male Sprague</p>	<p>High levels of BPAF were detected in liver, kidney and serum. BPAF was also detected in other organs, such as testis.</p> <p>The liver seemed to be the main organ responsible for metabolism.</p>		Yang et al. 2012.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Method	Results	Remarks	Reference
Dawley rats, for 2 consecutive weeks. Urine and feces samples were collected, as well as serum and tissues, including kidneys, liver, testis, adipose and muscle.	The highest level of BPAF was found in feces (in unconjugated form).		
Test substance: BPAF Non-test guideline, in vivo experimental study. For urine analysis: BPAF (98% purity) was given orally (200 mg/kg) to 8 weeks-old male Sprague-Dawley rats, daily, for 2 consecutive weeks. No information was found on the number of animals used. For serum analysis: 6 animals per treatment group were given a single oral dose of 20 mg/kg or 100 mg/kg.	Four metabolites of BPAF were identified in urine: BPAF diglucuronide, BPAF glucuronide, BPAF glucuronide dehydrated and BPAF sulfate. BPAF glucuronide was the major metabolite formed in vivo. Glucuronidation was a rapid and efficient pathway for biotransformation of BPAF. The peak of BPAF glucuronide in plasma was observed at 30 minutes after treatment, followed by a rapid decline in the next 3 hours, indicating a fast clearance in rats. The peak of BPAF was observed at 1 hour, and was completely eliminated after 48 hours. The three other metabolites were not found in plasma.		Li et al. 2013

9.1 Short summary and overall relevance of the provided toxicokinetic information on the proposed classification.

No toxicokinetic studies on benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate are available. The section on toxicokinetics is based on data available on BPAF in the open literature.

Absorption

Oral

In rats and mice, BPAF was rapidly absorbed after oral administration. The bioavailability was low (Waidyanatha et al. 2015).

Dermal

No dermal absorption study is available with BPAF.

Inhalation

No inhalation absorption study is available with BPAF.

Distribution

High levels of BPAF has been detected in gall bladder (Waidyanatha et al. 2015) and in liver, kidney and serum in rats after oral administration (Yang et al 2012). BPAF has also been detected in other organs, such as testis, after oral exposure. BPAF given orally to female rats during gestation and lactation showed that BPAF could transfer via cord blood and breast milk and distribute to offspring testes (Li et al. 2016).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Metabolism

The liver seems to be the major organ responsible for metabolism (Yang et al 2012). Four metabolites of BPAF has been identified in urine: BPAF diglucuronide, BPAF glucuronide, BPAF glucuronide dehydrated and BPAF sulfate. BPAF glucuronide was the major metabolite formed in vivo. Glucuronidation was rapid and efficient pathway for biotransformation of BPAF (Li et al. 2013). The peak of BPAF glucuronide in plasma was observed at 30 minutes, followed by a rapid decline in the next 3 hours. The peak of BPAF was observed at 1 hour, and BPAF was completely eliminated after 48 hours (Li et al. 2013).

Elimination

Waidyanatha et al. (2015) showed that BPAF was excreted primarily via bile. BPAF was found mainly in feces by 72 h in both rats and mice after oral administration (Waidyanatha 2015). The majority of fecal radioactivity (> 94%) was in the form of BPAF. BPAF metabolites are excreted via urine (Li et al. 2013). Female mice excreted a larger proportion of the dose in urine compared to male mice, and male mice excreted more in feces, compared to females (Waidyanatha et al. 2015).

10 EVALUATION OF HEALTH HAZARDS

10.1 Acute toxicity oral route

Not evaluated in this CLH proposal.

10.2 Acute toxicity dermal route

Not evaluated in this CLH proposal.

10.3 Acute toxicity inhalation route

Not evaluated in this CLH proposal.

10.4 Skin corrosion/irritation

Not evaluated in this CLH proposal.

10.5 Serious eye damage/eye irritation

Not evaluated in this CLH proposal.

10.6 Respiratory sensitisation

Not evaluated in this CLH proposal.

10.7 Skin sensitisation

Not evaluated in this CLH proposal.

10.8 Germ cell mutagenicity

Not evaluated in this CLH proposal.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

10.9 Carcinogenicity

Not evaluated in this CLH proposal.

10.10 Reproductive toxicity

10.10.1 Adverse effects on sexual function and fertility (data on BPAF)

Data on BPAF is used as the basis for this CLH proposal. Benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate is a 1:1 salts of a BPAF-based anion moiety, and a cation. The substance thus contains ca 50% BPAF.

Table 9: Summary table of animal studies on adverse effects on sexual function and fertility

Method, guideline, deviations if any, species, strain, sex, no/group	Test substance, dose levels duration of exposure	Results	Reference
<p>Combined repeated dose toxicity study with reproduction/developmental toxicity screening test (oral:gavage) according to GLP.</p> <p>OECD Test Guideline 422</p> <p>Rat (Sprague-Dawley) male/female</p> <p>Treatment groups: 12 males + 12 females per treatment group.</p> <p>Recovery groups: 5 males + 5 females per treatment group.</p> <p>Reliability Score 1 according to registrant</p>	<p>2,2-Bis (4-hydroxyphenyl)-hexafluoropropane (Bisphenol AF). Purity 99.69%.</p> <p>Dose levels: 0, 30, 100, 300 mg/kg bw/day.</p> <p>Duration of exposure: Test groups and controls: 55 consecutive days (including a 2 week maturation phase, pairing, gestation and early lactation for females),</p> <p>Recovery groups: treated for 42 consecutive days and then maintained without treatment for 14 days Recovery animals were not mated.</p>	<p>Pregnancy rates were reduced at all doses tested. None of the rats exposed to the highest dose (300 mg/kg bw/day) did achieve pregnancy. Fertility index was 100%, 83%, 64% and 0% for control, low, mid and high dose, respectively.</p> <p>Reproductive organs, including epididymides and testes, were significantly smaller (20 and 11%, respectively) in male rats treated at the highest dose (300 mg/kg bw/day).</p> <p>Female rats treated with BPAF (30 and 100 mg/kg bw/day) demonstrated significantly lower mean body weight (7-10%) during gestation and lactation periods.</p>	<p>Study report, 2011.</p>
<p>OECD Test Guidelines 407 Repeated Dose 28-day Oral Toxicity Study in Rodents, GLP compliant.</p> <p>Rats Crj:CD(SD) rats</p> <p>Reliability Score 1 according to registrant</p>	<p>4,4´- (Hexafluoroisopropylidene)diphenol (Bisphenol AF)</p> <p>Dose levels: 0, 10, 30, 100 mg/kg/day</p> <p>Duration of exposure: 28 days, beginning at 8 weeks of age.</p>	<p>Significantly lower body weight gains (12%) were seen in high dose male rats.</p> <p>The absolute weights of reproductive organs, such as prostate and seminal vesicles were significantly lower in high dose males (-23 and -28%, respectively)</p>	<p>Umano et al. 2012.</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Method, guideline, deviations if any, species, strain, sex, no/group	Test substance, dose levels duration of exposure	Results	Reference
		compared to controls. Furthermore, significant atrophy of Leydig cells was seen in high dose treated rats.	

Table 10: Summary table of human data on adverse effects on sexual function and fertility

Type of data/report	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
No data				

Table 11: Summary table of other studies relevant for toxicity on sexual function and fertility

Type of study/data	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
Uterotrophic assay GLP compliant Reliability Score 3 according to registrant	BPAF: Purity 98.8%.	Crj:CD rats, 19-days-old at the start of the experiment, 6 animals per dose group. Dose levels: 0, 8, 40, 100 mg/kg/day Duration of exposure: subcutaneous injection for 3 consecutive days.	BPAF exposure caused significantly increased uterine blotted weight at all doses tested. In addition, watery uterine contents were grossly detected in the high dose group (100 mg/kg). The body weights of treated animals were not significantly different compared to control animals.	Yamasaki et al. 2003.
Hershberger assay GLP compliant Reliability Score 3 according to registrant	BPAF: Purity 98.8%.	Male BRL Han:WIST Jcl (GALAS) rats, 6 animals per dose group. Dose levels: 0, 50, 200, 600 (400*) mg/kg/day Duration of exposure: oral gavage for 10 consecutive days, beginning at postnatal days 56. *Dose was reduced because toxic signs were observed during the study.	BPAF exposure at 600 mg/kg caused a significant increase in relative glans penis weight. However, there were signs of general toxicity at the two highest doses which included significantly decreased body weight gain and decreased spontaneous locomotion. In addition, the control values varied considerably and an androgen agonistic property could not be determined in this study.	Yamasaki et al. 2003.
Non-guideline study, in vivo experimental	BPAF	Doses: 0, 2, 10, 50, 200 mg/kg bw/day Duration of exposure: 14 days.	The concentrations of BPAF in the testes increased with increasing dose. Cholesterol levels in serum decreased significantly in animals in the two highest dose groups.	Feng et al. 2012.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Type of study/data	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
<p>I study</p> <p>Species, strain and sex: Adult rats (Sprague Dawley) males</p> <p>Treatment groups: 8 animals per group.</p>			<p>Testosterone in serum decreased significantly in the high dose group, whereas luteinizing hormone and follicle-stimulating hormone increased. Testicular mRNA levels of Inhibin B, estrogen receptor and lutenising hormone receptor decreased in high-dose animals.</p>	
<p>Zebrafish exposed to BPAF from 4 hour post-fertilization to 120 day-post-fertilization</p> <p>OECD TG 236</p>	BPAF	<p>Long-term effects of BPAF on hormonal balance and genes of hypothalamus-pituitary-gonad axis and liver of zebrafish, and the impact on offspring were studied.</p> <p>Dose levels: 0, 5, 25, 125 µg/L</p>	<p>The fertilization rate of spawn eggs was significantly decreased at the highest concentration tested. In the F1 generation, the malformation rate was significantly increased in the high dose group, and survival rate was lower compared to controls.</p> <p>Male zebrafish (F0) exposed to BPAF had significantly increased concentrations of plasma 17β-estradiol (E2) compared to controls, and significantly decreased levels of plasma testosterone. In females (F0), E2 levels were significantly increased in the high dose group.</p> <p>Vitellogenin gene expression was significantly increased in the liver of treated male zebrafish (F0).</p> <p>In the testis, expressions of fshr, cyp19a and cyp11a1 were significantly increased in the high dose group, and star and cyp17 were significantly decreased.</p> <p>In ovaries, fshr was significantly increased and star was decreased, compared to control group.</p>	Shi et al. 2015
<p>Zebrafish exposed to BPAF for 28 days.</p>	BPAF	<p>Dose levels: 0, 0.05, 0.25, 1.0 mg/L</p>	<p>Exposure to 1 mg/L BPAF caused liver damaged in male fish, but no effects were seen in females. The highest dose affected the testis and caused a retardation of oocyte development in the ovaries.</p> <p>In male fish, the testosterone levels decreased dose-dependently, while estradiol levels increased (at 1.0</p>	Yang et al. 2016

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

Type of study/data	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
			mg/L in males and at 0.05 and 0.025 mg/L in females). Upregulated vitellogenin was seen in both sexes.	
Zebrafish exposed to BPAF for 21 days.	BPAF	Transcription of genes related to thyroid endocrine disruption in male zebrafish following exposure to BPAF was studied. Dose: 24.7 µg/L	BPAF affected genes related to thyroid hormones production and receptor activation, thyroid gland development and deiodinase activity.	Kwon et al. 2016
Zebrafish larvae exposed to BPAF short-term. OECD TG 236	BPAF	Whole-body total 3,3',5-triiodothyronine, total 3,5,3',5'-tetraiodothyronine, free 3,3',5-triiodothyronine and free 3,5,3',5'-tetraiodothyronine levels were examined following 168 h post-fertilization exposure to BPAF. Dose levels: 0, 5, 50, 500 µg/L	The results showed that thyroid hormones decreased significantly after BPAF treatment, indicating endocrine disruption of the thyroid. The expression of genes involved in the hypothalamic-pituitary-thyroid axis was also affected by BPAF exposure.	Tang et al. 2015
In vitro study in human breast cancer cells	BPAF		Binding of BPAF to G protein-coupled estrogen receptor (GPER). BPAF had a 9-fold stronger binding affinity than BPA. BPAF exhibited stronger agonistic activity to GPER compared to BPA.	Cao et al. 2017
In vitro study in human cervical cancer cell line (HeLa)	BPAF		BPAF bound to estrogen receptor with a receptor-binding activity three times stronger for ERβ than for ERα. BPAF fully activated ERα in a dose-dependent manner, but was almost completely inactive for ERβ.	Matsushima et al. 2010
In vitro study in human breast cancer cell lines	BPAF		BPAF functioned as an agonist of ERα at lower concentrations (nanomolar order), and as an anti-estrogenic compound via the induction of ERβ at higher concentrations.	Okazaki et al. 2017
In vitro study in human breast cancer cell lines	BPAF		Estrogenicity of BPA analogues was studied. BPAF exposure stimulated cell growth in an ER-mediated cell proliferation assay and induced estrogen response element-mediated transcription in a luciferase assay. BPAF was the most potent BPA analogue, followed by BPB, BPZ, BPA,	Mesnager et al. 2017

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

Type of study/data	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
			BPAP and BPS.	
In vitro study in human breast cancer cell line and two-hybrid yeast screen systems	BPAF		BPAF was more potent than BPA for estrogenic and thyroidal effects in yeast (ER α and thyroidal hormone receptor agonistic activity).	Lei et al. 2017
In vitro study in human adrenocortical cell line	BPAF		Exposure to BPAF altered steroidogenesis in H295R cells. BPAF induced progesterone and reduced testosterone levels. BPAF was more potent in inducing cell toxicity compared to BPA, BPS and BPF.	Feng et al. 2016
In vitro study in Yeast (XenoScreen XL YES/YAS assay)	BPAF		BPAF demonstrated agonistic estrogenic activity in a yeast assay. BPAF was more potent than BPA. BPAF also showed anti-androgenic activity with a higher potency compared to BPA.	Fic et al. 2014
In vitro study: NIH3T3 Luciferase Reporter Assay	BPAF		BPAF demonstrated clear agonistic estrogenic activity in the MCF-7 Estrogen Luciferase Reporter Assay. BPAF showed inhibitory effects on the androgenic activity of 5 α -dihydrotestosterone in mouse fibroblast cell line NIH3T3.	Kitamura et al. 2005
In vitro study in African green monkey kidney CV1 cells	BPAF		BPAF demonstrated agonistic estrogenic activity and acted as an AR antagonist in this luciferase reporter assay.	Teng et al. 2013

10.10.2 Short summary and overall relevance of the provided information on adverse effects on sexual function and fertility

Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD TG 422) of BPAF in rat (Study report, 2011)

In an OECD TG 422 guideline study, BPAF was administered by gavage to 3 dose groups each of 12 male and 12 female Sprague-Dawley CrI:CD (SD) IGS BR Strain rats, for 55 days (including a 2 week maturation phase, pairing, gestation and early lactation for females), at dose levels of 30, 100 and 300 mg/kg/day. A control group of 12 males and 12 females was dosed with vehicle alone (Arachis oil BP).

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

Two recovery groups (5 males and 5 females), were treated with the high dose (300 mg/kg/day) or the vehicle alone for 42 consecutive days and then maintained without treatment for 14 days. Recovery animals were not mated.

Fertility, parturition and sexual function

The number of pairing days until mating did not vary significantly between controls and treated animals (in average 3.9 days for controls and 4.0 days for high dose animals). The number of estrous stages without mating was slightly higher in mid- and high dose females compared to control animals (0.9 ± 1.3 and 0.6 ± 1.2 , vs. 0 in controls). Irregular estrous cycles were observed in 2 of 11 high dose animals (18%) and in 1 of the mid dose females (8%).

Sperm reading scores (based on number of sperm detected) indicate sperm effects from treatment, since high dose males had scores of 0 (n=1), +1 (n=3), +2 (n=1) and +3 (n=5) compared to control males, which all had scores of +3 (n=11). (1+ Few spermatozoa present, 2+ Continuous few spermatozoa in all fields, 3+ Many spermatozoa in all fields)

The mating index did not differ significantly between controls and treated animals (91% in high dose animals vs 92% in controls) (Table 12). However, exposure to BPAF did have a clear impact on the pregnancy outcomes, since no pregnancy was induced in any of the high dose females that mated (10 of 11 animals, since 1 animal pair did not mate). The incidence of non-pregnant females increased with increasing dose and the fertility index was 100%, 83%, 64% and 0 for controls, low-, mid- and high dose groups, respectively.

Pre-implantation losses were higher in mid dose animals compared to controls (19% vs. 12%), however not significantly higher. There were large individual variations within the dose groups, which resulted in large standard deviations for this parameter. The number of corpora lutea and implantations were lower in treated females compared to controls (14.0 vs. 16.7 and 10.4 vs. 14.1, respectively), however, not significantly lower (Table 12). Implantation index was lower, 81% in mid dose females vs. 88% in controls. Total litter loss was observed for one female each of the low- and mid dose group, compared to none among control females.

Table 12: Fertility parameters, OECD TG 422 study, 2011

Dose levels (mg/kg bw/day)	0	30	100	300
No. of pairs examined	12	12	12	11
Estrous cycle (days)	4.0 ± 0.0	3.9 ± 0.2	4.3 ± 0.4	4.2 ± 0.2
Irregular estrous cycle	0/12	0/12	1/12 (8%)	2/11 (18%)
No. of pairs with successful mating	11	12	11	10
Mating index (%) = (No. of pairs with successful mating/ No. of pairs examined) X 100	91.7	100.0	91.7	90.9
No. of pregnant females	11	10	8	0
Fertility index (%) = (No. of pregnant animals/ No. of pairs with successful mating) x 100	100.0	83.3	63.6	0
Pairing days until mating	3.9 ± 3.5	2.3 ± 1.3	2.4 ± 1.4	4.0 ± 4.1
No. of estrous stages without mating	0.0 ± 0.0	0.0 ± 0.0	0.6 ± 1.2	0.9 ± 1.3
Total litter loss in utero	0	1 of 10 (10%)	1 of 8 (13%)	-
Gestation length (days)	22.9 ± 0.6	23.0 ± 0.6	22.9 ± 0.2	-

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

No. of corpora lutea	16.7 ± 3.6	14.7 ± 5.8	14.0 ± 7.8	-
No. of implantations	14.1 ± 1.9	12.1 ± 3.8	10.4 ± 4.8	-
Implantation index (%) = (No. of implantation sites/ No. of corpora lutea) x 100	88.1 ± 13.2	89.4 ± 18.2	81.3 ± 16.8	-
Pre-implantation loss (No. of corpora lutea - No. of implantation sites/No. of corpora lutea x 100) (mean %)	11.9 ± 13.2	10.6 ± 18.2	18.7 ± 16.8	-

Reproductive organ weights and histopathology

Males

The absolute weights of the epididymides and testes were significantly lower in the high dose males compared to control animals (20 and 11%, respectively) (Annex I, Table 3). Similarly, the relative weight of epididymides in the high dose group was significantly lower (13%) compared to control animals.

Significantly reduced secretory content in the prostate was seen in treated animals and the incidence increased with increasing dose (Table 13). This effect was present in 67% of high dose animals and in 80% of high dose recovery males, compared to none in control animals. In addition, significantly reduced secretory content of seminal vesicles was observed in all high dose males (in 100% vs. 8% of control animals) and the incidence increased with increasing dose.

Leydig cell atrophy was present in 11 of 12 high dose males (92%) compared to 1 of 12 (8%) of control animals (Table 13). In the mid dose group, 3 of 12 males showed this effect. There was also moderate to severe atrophy of testes in 2 of 5 high dose recovery males.

Fifty percent of high dose males showed tubuloalveolar differentiation of the mammary glands (slight and moderate effects) (Table 13). In high dose recovery males, 4 of 5 animals demonstrated this effect. No effects on mammary glands were seen in control animals.

Table 13: Number of male animals with histopathological findings in reproductive-related organs. Incidence in percent in parenthesis. Study report, 2011

Dose levels (mg/kg/day)	0	30	100	300	Recovery 0	Recovery 300
No. of animals	n = 12	n = 12	n = 12	n = 12	n= 5	n= 5
Mammary gland - Tubuloalveolar differentiation						
No section	2	2	2	3	0	0
Absent	7	4	3	1	5	1
Minimal	3 (25%)	4 (33%)	6 (50%)	2 (17%)	0	0
Slight	0	2 (17%)	1 (8%)	4 (33%)	0	1 (20%)
Moderate	0	0	0	2 (17%)	0	3 (60%)
Prostate - Reduced secretory content						
No section	0	0	1	0	0	0
Absent	23	11	7	4	5	1

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

Dose levels (mg/kg/day)	0	30	100	300	Recovery 0	Recovery 300
Present	0	1 (8%)	4 (33%)	8 (67%)	0	4 (80%)
Prostate - Chronic inflammatory cell foci						
Absent	12	12	11	11	5	5
Slight	0	0	0	1 (8%)	0	0
Seminal vesicles – Reduced secretory content						
Vesicle 1						
No section	0	0	1	0	0	0
Absent	11	10	5	0	5	2
Present	1 (8%)	2 (16%)	6 (50%)	12 (100%)	0	3 (60%)
Vesicle 2						
No section	0	0	1	0	5	5
Absent	11	10	6	0	0	0
Present	1 (8%)	2 (16%)	5 (42%)	12 (100%)	0	0
Testes - Atrophy						
Testis 1						
Absent	12	12	12	12	5	3
Moderate	0	0	0	0	0	1 (20%)
Severe	0	0	0	0	0	1 (20%)
Testis 2						
Absent	12	12	12	12	5	4
Severe	0	0	0	0	0	1 (20%)
Leydig cell						
Absent	11	12	9	1	5	4
Present	1 (8%)	0	3 (25%)	11 (92%)	0	1 (20%)

Pregnant females

In mid dose females that got pregnant, a higher incidence of follicular/fluid-filled cysts in the ovaries was observed compared to controls (43% vs. 18%) (Annex I, Table 6).

Cystic corpora lutea were found in the ovaries among both pregnant controls and treated animals (in 45% of control animals, vs. 14% in mid dose females).

Non-pregnant females

Minimal glandular hyperplasia of the mammary gland was seen in 4 of 11 (36%) of the high dose group among non-pregnant females (Table 14). Ovarian cysts were found in several of the non-pregnant females of

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

each treatment group. Nine of the non-pregnant high dose females (82%) had follicular/fluid-filled cysts on the ovaries, which was absent in the control female that did not mate. In addition, a higher incidence of follicular/fluid-filled cysts in the ovaries was found in 4 of 5 (80%) of the high dose recovery females (Annex I, Table 6).

Five of 11 (45%) of the high dose (non-pregnant) females had minimal follicular cell hypertrophy of the thyroid, an effect also noted in 1 animal in the low dose group. However, since the number of non-pregnant females was much lower in the lower dose groups and controls, the incidence results should be interpreted with caution.

Effects of uterus/cervix and vagina (dilatation horn, endometrial gland proliferation and keratinisation cervix and epithelial hyperplasia, epithelial keratinisation and keratin cysts, respectively) were observed in a few non-pregnant female animals of all dose groups, but not in the single non-pregnant control female. Epithelial hyperplasia of the vagina was seen in 4 (36%) of the non-pregnant high dose females compared to none in the other dose groups.

Table 14: Number of female animals with histopathological findings in reproductive-related organs, only females that failed to mate/non-pregnant. Incidence in percent in parenthesis. Study report, 2011

Dose levels (mg/kg/day)	0	30	100	300
No. of animals	n=1	n=2	n= 4	n= 11
No. animals that failed to mate	1 of 12 (8%)	0	1 of 12 (8%)	1 of 11 (9%)
No. of animals not pregnant	0	2 of 12 (16%)	3 of 12 (25%)	10 of 11 (90%)
Mammary gland				
Glandular hyperplasia (minimal)	0	0	0	4 of 11 (36%)
Ovaries				
Cystic corpora lutea	0	1 of 2 (50%)	1 of 4 (25%)	3 of 11 (27%)
Follicular/fluid-filled cyst	0	0	2 of 4 (50%)	9 of 11 (82%)
Haemorrhagic cyst	0	0	0	1 of 11 (9%)
Vacuolation stroma	0	0	0	2 of 11 (18%)
Thyroid				
Follicular cell hypertrophy (minimal)	0	1 of 2 (50%)	0	5 of 11 (45%)
Uterus/Cervix				
Dilatation horn 1				
Minimal	0	0	1 of 4 (25%)	1 of 11 (9%)
Slight	0	1 of 2 (50%)	1 of 4 (25%)	1 of 11 (9%)
Dilatation horn 2				
Minimal	0	0	2 of 4 (50%)	1 of 11 (9%)
Slight	0	1 of 2 (50%)	0	1 of 11 (9%)
Endometrial gland proliferation	0	0	0	1 of 11 (9%)
Keratinisation cervix	0	2 of 2 (100%)	3 of 4 (75%)	1 of 11 (9%)

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Vagina				
Epithelial hyperplasia				
Minimal	0	0	0	4 of 11 (36%)
Epithelial keratinisation	0	2 of 2 (100%)	1 of 4 (25%)	2 of 11 (18%)
Keratin cyst	0	0	0	1 of 11 (9%)

General toxicity

Clinical signs included increased salivation and staining around the mouth post-dosing for animals in all treatment groups (in a dose-response manner). Dehydration and staining around the ano-genital region was observed for two high dose females. One high-dose female, which was killed on Day 6, demonstrated severe clinical signs that were considered caused by incorrect administration of the test substance. There were no effects observed related to behaviour, functional performance or sensory reactivity in any of the treated groups.

No significant changes in mean body weights for the treated males were seen, although there was a tendency of lower weights among animals in mid- and high dose groups compared to controls (Annex I, Table 3). In recovery males, however, significant lower mean weights were demonstrated in treated animals (16% and 22% compared to controls, on days 22 and 43, respectively) (data not shown). It is noted that recovery control males had a higher mean body weight than non-recovery control males. Two weeks off treatment the weights of high dose treated animals (recovery group) were still significantly lower compared to controls (17%).

Table 15: Mean female body weights (g), Study report, 2011

Dose levels (mg/kg/day)	0	30	100	300
Maturation, No. of females	n = 12	n = 12	n = 12	n = 11
Day 1	241 ± 15	238 ± 14	233 ± 10	242 ± 11
Day 15	256 ± 15	246 ± 17	239 ± 14	250 ± 16
Gestation, No. of females	n = 11	n = 9	n = 6	No pregnant animals
Day 0	271 ± 20	253 ± 22	248 ± 17	
Day 20	421 ± 31	377* ± 32 (-10%)	382 ± 39	
Lactation, No. of females	n = 11	n = 9	n = 7	
Day 0	324 ± 20	301* ± 27 (-7%)	292* ± 13 (-10%)	
Day 4	332 ± 24	300** ± 25 (-10%)	301* ± 15 (-9%)	

*p<0.05, **p<0.01

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4- HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

The mean body weight *change* during week 1 of maturation was significantly lower in the mid- and high dose groups compared to control (0 and 1%, respectively, compared to 4% for control animals). However, there were no significant differences on mean body weights among females in the different dose groups during maturation weeks 1 and 2. A significantly lower mean body weight (10%) was observed for females in mid dose group compared to controls at day 20 of gestation (Table 15). During lactation (day 0 and 4) both the low- and mid dose group females demonstrated significantly lower mean body weights compared to controls (range: 7 to 10%). Among recovery females there were no significant differences in body weights between control and exposed animals (measured at days 1, 8, 15, 22, 29, 36, 43, 50 and 57).

Among treated males, the mean food consumption was significantly lower in the two highest dose groups (9% and 22%, respectively) during the first week of treatment. Treated females (mid- and high dose groups) also demonstrated significantly lower food consumption during maturation week 1 (19% and 25% compared to controls, respectively). During gestation days 7-14, females in the low- and mid dose groups had a lower food intake (13%) and during days 14-20, the mid dose group demonstrated lower food intake (11%) compared to controls. No high dose females (non-pregnant) were included in comparative evaluations after maturation and mating weeks.

Water consumption in males was significantly higher among animals in all treatment groups compared to controls at all assessments points (week 1-2 and weeks 5-6). In the high dose group, water consumption ranged between +19% and +39% compared to controls. Water consumption increased significantly also in treated females during pre-mating days 1-7 (mid- and high dose groups), with an increase of 30% and 39% compared to controls, respectively, and during days 8-14 (high dose group; 11%).

Few changes of hematology parameters or blood chemistry of toxicological relevance/significance were reported. Measurements were conducted at day 14 and day 42/day 4 post partum. Significant reductions in haemoglobin and erythrocyte counts in high dose males were demonstrated prior to termination on day 42 (8 and 9%, respectively). Furthermore, ALAT values were significant higher (35-37%) in mid- and high dose males compared to control animals at day 42. Among high dose female rats, the ALAT value was significantly higher (74%) compared to control animals during the maturation phase (day 14).

The mean relative weights of adrenals and liver were significantly higher in males of the high dose group (25 and 10%, respectively) compared to controls (Annex I, Table 3). In recovery animals, the mean absolute liver weight of the high dose males was significantly lower compared to control animals (18%) and relative organs weights for adrenal, brain, spleen and thymus were significantly higher compared to controls (data not shown).

The mean relative brain weights of females in the low- and mid dose groups were significant higher compared to controls (7% and 9%, respectively) (Annex I, Table 3). Likewise, the mean absolute heart weights were significantly lower in the low- (17%) and mid dose (15%) females compared to control animals. No significant effects on organ weights were seen in treated recovery females (data not shown). Non-pregnant females in the high dose group were not included in comparative evaluations after maturation and mating.

Conclusion

A clear effect on fertility was evident in high dose animals (300 mg/kg bw/day) in the Study report, 2011. Among the females treated at this dose level, which mated, no pregnancies were achieved. The incidence of animals without induced pregnancy increased with increasing dose starting from the lowest dose (30 mg/kg bw/day). No marked general toxicity was noted.

28-day repeated dose toxicity test (OECD TG 407) of BPAF in rats (Umano et al. 2012)

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

A repeated-dose toxicity study conducted according to the OECD test guideline 407 (in vivo screening tests to detect endocrine-mediated effects) was performed using Crj:CD rats. Rats were orally gavaged for 28 days with 0, 10, 30 and 100 mg/kg bw/day BPAF, each dose group comprised 10 males and 10 females.

Reproductive organs and histopathology

Absolute weights of prostate, ventral prostate, and seminal vesicle were significantly lower in the high dose group (23%, 25%, and 28%, respectively) (Table 16).

Histopathological findings demonstrated significant atrophy of testicular Leydig cells in high dose males (Table 17). Atrophy of the mammary glands was also seen in 3 of 10 males in the high dose group, compared to none in the other groups, however this effect was not significantly altered compared to controls.

A sperm analysis did not reveal any abnormalities in treated males.

In females, there were no signs of histopathological effects. However, irregular estrous cycles were observed in females in mid- and high dose groups.

General toxicity

In the high dose group of male rats, mean body weights were significantly lower (12%) compared to controls (Table 16), an effect also seen in females rats in the mid- (7%) and high dose (8%) groups. In high dose males white blood cell counts, total cholesterol and albumin values were significantly lower. Among female rats cholinesterase and total cholesterol values were lower than for controls, and total bilirubin values were higher among high dose animals. Serum T4 levels were significantly higher in the high dose group of both sexes, compared to controls.

Organ weight measurements revealed significantly higher relative weights in high dose males of kidney (9%), adrenals (23%) and brain (15%), whereas liver (18%), heart (12%) and spleen (17%) were significantly lower in this dose group. Histopathological examination revealed significant hypertrophy of the adrenal zona fasciculata, and decreased hepatocytic glycogen in the high dose males, compared to controls (Table 17). Among high dose females the absolute heart weight was significantly lower (10%) and the relative brain weight was higher (8%) (Table 16).

Conclusion

Significantly lower absolute weights of reproductive organs were observed among BPAF treated males. The effects observed on mammary glands in males, testis and estrous cycle indicate endocrine-mediated (estrogenic) mechanisms underlying the toxicity of BPAF.

Table 16: Body weights and organ weights (mean ± SD) (Umano et al. 2012)

Dose levels (mg/kg/day)	0	10	30	100
Males	n = 9	n = 10	n = 10	n = 10
Initial body weight (g)	324 ± 14	324 ± 13	325 ± 15	326 ± 13
Terminal body weight (g)	449 ± 27	451 ± 26	450 ± 33	396** ± 29
Prostate (mg)	1068 ± 188	1134 ± 179	1061 ± 189	827* ± 183
Prostate (g/100 g)	0.237 ± 0.045	0.251 ± 0.031	0.236 ± 0.041	0.208 ± 0.039
Ventral prostate (mg)	631 ± 166	741 ± 110	676 ± 150	474* ± 112
Ventral prostate (g/100 g)	0.139 ± 0.034	0.164 ± 0.021	0.150 ± 0.030	0.120 ± 0.027

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Dose levels (mg/kg/day)	0	10	30	100
Seminal vesicle (g)	1.41 ± 0.19	1.43 ± 0.30	1.38 ± 0.24	1.02* ± 0.36
Seminal vesicle (g/100 g)	0.312 ± 0.045	0.317 ± 0.069	0.307 ± 0.045	0.254 ± 0.079
Liver (g)	17.13 ± 2.18	16.90 ± 1.37	16.38 ± 2.85	14.10** ± 1.31
Liver (g/100 g)	3.778 ± 0.322	3.747 ± 0.179	3.623 ± 0.399	3.564 ± 0.271
Kidney (g)	3.02 ± 0.23	3.01 ± 0.18	3.00 ± 0.37	2.89 ± 0.30
Kidney (g/100 g)	0.667 ± 0.021	0.671 ± 0.058	0.666 ± 0.064	0.729* ± 0.043
Heart (g)	1.28 ± 0.09	1.32 ± 0.08	1.28 ± 0.09	1.13** ± 0.13
Heart (g/100 g)	0.283 ± 0.013	0.293 ± 0.018	0.285 ± 0.011	0.286 ± 0.017
Spleen (g)	0.71 ± 0.08	0.70 ± 0.08	0.71 ± 0.10	0.59* ± 0.09
Spleen (g/100 g)	0.158 ± 0.018	0.155 ± 0.015	0.158 ± 0.020	0.149 ± 0.016
Adrenals (mg)	58 ± 8	58 ± 11	56 ± 4	63 ± 9
Adrenals (g/100 g)	0.013 ± 0.002	0.013 ± 0.002	0.012 ± 0.001	0.016** ± 0.003
Brain (g)	2.17 ± 0.05	2.21 ± 0.09	2.23 ± 0.06	2.19 ± 0.07
Brain (g/100 g)	0.482 ± 0.034	0.491 ± 0.032	0.498 ± 0.036	0.554** ± 0.035
Females	n = 10	n = 10	n = 10	n = 10
Initial body weight (g)	211 ± 7	215 ± 11	213 ± 10	214 ± 11
Terminal body weight (g)	274 ± 18	277 ± 18	255* ± 18	253* ± 15
Heart (g)	0.87 ± 0.08	0.88 ± 0.05	0.82 ± 0.11	0.78* ± 0.06
Heart (g/100 g)	0.316 ± 0.015	0.319 ± 0.021	0.321 ± 0.024	0.308 ± 0.020
Brain (g)	2.03 ± 0.05	2.00 ± 0.06	2.05 ± 0.10	2.02 ± 0.08
Brain (g/100 g)	0.742 ± 0.042	0.725 ± 0.044	0.809* ± 0.070	0.799* ± 0.039

*Significantly different from control, p<0.05 ** Significantly different from control, p<0.01

Table 17: Significant histopathological findings in male rats (Umano et al. 2012)

Dose levels (mg/kg/day)	0	10	30	100
Testis: atrophy of Leydig cells	0	0	0	5*
Adrenal gland: hypertrophy of zona fasciculata	1	1	0	8**
Liver: decreased hepatocytic glycogen	1	0	1	8**

*Significantly different from control, p<0.05 ** Significantly different from control, p<0.01

Uterotrophic assay and Hershberger assay, Yamasaki et al. 2003

Yamasaki et al. studied estrogenic and androgenic effects of BPAF given on 3 consecutive days to 19-day-old rats in the uterotrophic assay, at doses 0, 8, 40 and 100 mg/kg per day, and for 10 consecutive days in the Hershberger assay at doses 0, 50, 200 and 600 mg/kg per day. BPAF tested positive in the uterotrophic assay (dose-response), with significantly increased uterine blotted weight at all doses tested, suggesting estrogenic agonistic properties of BPAF. In addition, watery uterine contents were detected in the high dose group (100 mg/kg) (Table 18). No significant differences on body weights were seen among treated animals, compared to controls.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

In the Hershberger assay (0, 50, 200 and 600 mg/kg) the relative glans penis weight increased significantly in rats given 600 mg/kg BPAF per day (Table 19). However, there were signs of general toxicity at the two highest doses which included significantly decreased body weight gain and decreased spontaneous locomotion. In addition, the control values for this organ varied considerable, and according to the authors an androgen agonistic property could not be determined in this study.

Table 18: Results from an uterotropic assay, Yamasaki et al. 2003

Dose levels (mg/kg/day)	0	8	40	100
Body weight (g)	56.1 ± 4.3	55.0 ± 4.5	56.6 ± 4.0	54.7 ± 4.2
Uterus blotted weight, absolute (mg)	28.6 ± 4.9	47.2** ± 9.9	65.9** ± 9.8	96.4** ± 9.0
Uterus blotted weight, relative (mg/100 g)	50.9 ± 7.4	85.1** ± 11.9	116.0** ± 11.7	177.2** ± 22.2

** Significantly different from control at p<0.01.

Table 19: Results from the Hershberger assay, Yamasaki et al. 2003

Dose levels (mg/kg/day)	0	50	200	600 (400)
Body weight (g)	275.1 ± 9.7	257.09 ± 18.2	259.99* ± 12.8	219.69 ± 30.9
Ventral prosate (mg/100 g bw)	5.89 ± 0.9	5.59 ± 1.5	5.79 ± 1.4	6.29 ± 1.6
Seminal vesicle (mg/100 g bw)	11.39 ± 2.1	12.09 ± 1.8	13.29 ± 2.3	13.69 ± 1.2
BC/LA (mg/100 g bw)	53.29 ± 6.3	55.99 ± 8.4	44.29* ± 4.7	48.99 ± 3.5
Glans penis (mg/100 g bw)	12.69 ± 1.0	12.89 ± 1.1	12.29 ± 2.0	15.19* ± 1.8
Cowper's gland (mg/100 g bw)	1.59 ± 0.5	1.79 ± 0.5	1.39 ± 0.4	1.79 ± 0.3

* Significantly different from control at p<0.05.

Mode of action – mechanistic information supporting adverse effects seen in vivo

Several mechanistic studies on the effects of BPAF in zebrafish, and in vitro, are available. Short summaries of these are found in Table 11. Results consistently indicate estrogenic and anti-androgenic effects of BPAF, mechanisms of relevance for the effects seen on fertility in vivo. Several in vitro studies also show that BPAF can cause DNA damage, oxidative stress and induce apoptosis (Lee et al. 2013, Mokra et al. 2017, Lei et al. 2017, Ding et al. 2017).

Summary of available studies

In an OECD TG 422 study (GLP compliant) BPAF was administered to 12 male and 12 female Sprague-Dawley rats, for 55 days (including a 2 week maturation phase, pairing, gestation and early lactation for females), at dose levels of 0, 30, 100 and 300 mg/kg/day.

A clear effect on fertility was evident in high dose animals. Among the females treated at this dose level, which mated, no pregnancies were achieved. The incidence of animals without induced pregnancy increased with increasing dose. Pre-implantation and post-implantation losses were higher in treated animals compared to controls, but not significantly different. Total litter loss was observed for one female each from the low- and mid dose groups, compared to none among control females.

Among high dose treated females (which all were non-pregnant), the incidence of follicular cysts of the ovaries was high (82%). The same effect was seen in 80% of high dose females (recovery group) compared

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4- HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

to none of the controls. In females that got pregnant (low- and mid-dose groups), the incidence of ovarian cysts increased with increasing dose. Effects on uterus/cervix and vagina were also observed in a few non-pregnant female animals of all dose groups, but not in the single control female that was non-pregnant.

In some of the treated females exposed to BPAF at 300 mg/kg bw/day in the OECD TG 422 study (and at 100 mg/kg bw/day in the OECD TG 407 study) irregular estrous cycles were seen. However, no differences were detected in the mating performance between controls and treated animals in the TG 422 study. In high dose males, absolute and relative weights of several reproductive organs were significantly smaller compared to controls, including epididymides and testes. In the 28-days repeated dose toxicity study (OECD TG 407), similar effects on males reproductive organs were seen in animals treated with BPAF at 100 mg/kg bw/day, including lower absolute weights of prostate and seminal vesicles. Correspondingly, histopathological effects were found in these organs, including Leydig cell atrophy in testes and reduced secretory content in prostate and seminal vesicles. In addition, tubuloalveolar differentiation and atrophy of mammary glands, were demonstrated among males of all dose groups, in both studies.

Although a few signs of systemic toxicity were observed in the Study report (2011) (reduced body weight, decreased food consumption, increased water consumption) the general toxicity of BPAF at the dose levels tested appears not to be marked. Thus, the reduced fertility seen at all doses (dose response) is considered a direct effect of the substance. Since treatment-related effects were seen in both treated males and females, both sexes may be affected by the substance, leading to a reduced fertility.

Results from the updated OECD TG 407 (28 days study with possibility to detect endocrine-mediated effects) demonstrated effects on mammary glands, testis and estrous cycle, indicating endocrine-mediated mechanisms involved (estrogenic effects). This result is in line with data from an uterotrophic assay that revealed significantly increased uterine blotted weight at all doses tested, suggesting estrogenic agonistic properties of BPAF. Several mechanistic studies on zebrafish and in vitro further support the estrogenic properties of BPAF. In addition, several comparative studies with BPA indicate a stronger estrogenic potency for BPAF.

BPAF is a structural analogue to BPA, which has a harmonised classification as Repr. 1B (H360F). Effects on sexual function and fertility of BPA mentioned as evidence in RAC's opinion¹ from 2014 include decreased ovarian weights and increased number of follicular cysts on ovaries in females, decreased serum testosterone and sperm production, and effects on reproductive organs in males.

Furthermore, adverse effects by BPA on fertility included decreased number of litters, litter size and number of live pups per litter, reported at 600 and 1200 mg/kg bw/day (mice) and at 500 mg/kg bw/day (rats)¹. Based on the findings summarised in the current proposal, BPAF seems to be more potent than BPA with a lower fertility index observed already at the lowest dose (30 mg/kg bw/day). However, it is not clear how the mechanisms underlying these effects differ from BPA.

10.10.3 Comparison with the CLP criteria

Since there are no studies on reproductive toxicity conducted on the substance benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate data on BPAF has been used as the basis for this CLH proposal. The substance is a 1:1 salts of a BPAF-based anion moiety, and a cation, and thus contains ca 50% BPAF.

The criteria for classification in Repr. 1B for adverse effects on sexual function and fertility are considered fulfilled since: A clear effect on fertility was evident in high dose animals in the Study report, 2011. Of the females treated at this dose level, which mated, no pregnancies were achieved. The incidence of animals without induced pregnancy increased with increasing dose.

¹ RAC Opinion proposing harmonised classification and labelling at EU level of Bisphenol A; 4,4'-isopropylidenediphenol: <https://www.echa.europa.eu/documents/10162/51436fe4-c531-e3aa-dbe8-42f9c75c83db>

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

In a total weight of evidence the available data provide clear evidence of an adverse effect on both male and female sexual function and fertility and there is no mechanistic evidence to indicate that the observed effects are not relevant for humans. Classification in Repr. 1B, H360F is therefore warranted.

Classification in Repr 1A is not appropriate as it should be based on human data and no human data are available.

Classification in Repr. 2 is not appropriate as the evidence for adverse effects on sexual function and fertility from existing experimental data on BPAF is considered as clear evidence and not some evidence.

10.10.4 Adverse effects on development

Table 20: Summary table of animal studies on adverse effects on development

Method, guideline, deviations if any, species, strain, sex, no/group	Test substance, dose levels duration of exposure	Results	Reference
<p>Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (oral:gavage) according to GLP.</p> <p>OECD Test Guideline 422</p> <p>Species, strain and sex: Rat (Sprague-Dawley) males and females</p> <p>Treatment groups: 12 males + 12 females per treatment group.</p> <p>Reliability Score 1 according to registrant</p>	<p>BPAF. Purity: 99.69%</p> <p>Doses: 0, 30, 100, 300 mg/kg bw/day.</p>	<p>Pregnancy rates were reduced at all doses tested. None of the rats exposed to the highest dose (300 mg/kg bw/day) did achieve pregnancy.</p> <p>Female rats treated with BPAF (30 and 100 mg/kg bw/day) demonstrated lower mean body weight (7-10%) during gestation and lactation periods, compared to controls. (High dose non-pregnant females were not included in comparative evaluations after maturation and mating).</p> <p>No adverse effects were seen on offspring exposed to BPAF in utero (30 and 100 mg/kg bw/day). However, no offspring was produced in the highest dose group (300 mg/kg bw/day).</p>	<p>Study report, 2011.</p>

Table 21: Summary table of human data on adverse effects on development

Type of data/report	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
No data.				

Table 22: Summary table of other studies relevant for developmental toxicity

Type of study/data	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
<p>Non-guideline study, in vivo experimental study</p> <p>Effects of</p>	<p>BPAF. Purity 98%</p>	<p>Doses: 0, 0.05, 0.5, 5 mg/kg bw given twice per day</p> <p>Species, strain and sex: Mice: CD-1 (Pregnant females)</p> <p>Treatment groups: 10-12</p>	<p>BPAF exposure caused accelerated pubertal mammary development.</p> <p>By 14 months of age, a significant dose-related</p>	<p>Tucker et al. 2018.</p>

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

Type of study/data	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
BPAF on development and long-term health of the mammary gland in female offspring was investigated.		animals per group. Duration of exposure: GD 10.5 to GD 17.5. Offspring was followed for up to 16 months.	increase in non-neoplastic lesions was found in BPAF-exposed groups, including cysts, inflammation, lobuloalveolar hyperplasia and squamous metaplasia.	
Non-guideline study, In vivo experimental study Effects of gestational and lactational exposure to BPAF on male offspring were studied. Reliability Score 4 according to registrant	BPAF. Purity 97%	Species, strain and sex: Rats: Sprague Dawley females Treatment groups: 30 females per dose group (GD 3-19), 15 females per dose group (PND 3-19). Doses: 0, 100 mg/kg bw/day Duration of exposure: GD 3 to GD 19 and PND 3 to PND 19.	Lactational exposure caused significantly increased levels of BPAF in serum and in testis, showing that BPAF was transferred via breast milk. Gestational and lactational exposure lead to increased testosterone and decreased Inhibin B levels in male offspring. Androgen receptor levels in testes increased following BPAF exposure.	Li et al. 2016.
Non-guideline in vivo study of the effects on maternal BPAF exposure during pregnancy on neurobehaviours in adolescent mice offspring.	BPAF	Pregnant mice were orally exposed daily from GD 1 to GD 19. On PND 35, 10 pups per litter were randomly selected to undergo behavioural tests. Doses: 0, 0.4, 4 mg/kg bw/day	Fetal exposure to BPAF induced anxiety- and depressive-like behaviours in male adolescent offspring. In addition, BPAF exposure impaired memory formation in both sexes.	Gong et al 2017.
OECD TG 236 Effects of BPAF exposure on zebrafish embryo-larvae	BPAF	Acute toxicity, teratogenic and estrogenic effects of BPAF were studied in zebrafish embryo-larvae. Doses: 0, 0.5, 0.75, 1.0 , 2.0 mg/L	BPAF was the most acute toxic substance among several bisphenols tested, and the most potent bisphenol of those tested for developmental effects. The substance caused cardiac edema. BPAF was the most potent studied estrogen in an estrogen-responsive transgenic fish Tg(ERE:Gal4ff)(UAS:GFP) among the chemicals tested in the study (e.g. BPA).	Moreman et al. 2017
Non-guideline	BPAF	BPAF was given to pregnant	BPAF exposure had no effect	Furr et al 2014.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Type of study/data	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
short-term in vivo study to detect disruption of fetal testosterone synthesis in rats exposed in utero.		rats from GD 14 to GD 18, the testes of fetal male rats were removed and incubated in media for ex vivo testis hormone production for 3 hours. Doses: 0, 200, 300, 400, 500 mg/kg bw	on testosterone levels at doses 200-500 mg/kg/day.	

10.10.5 Short summary and overall relevance of the provided information on adverse effects on development

Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD TG 422) in rat on BPAF, Study report, 2011

In the OECD TG 422 study described in more detail above (section 10.10.2), no significant effects were seen on offspring treated in utero. There were no differences in sex ratio and body weights of offspring between treated animals and controls. Table 13 in Annex I shows necropsy findings in offspring. No evident effects from BPAF treatment is noted. The pups were examined until PND 5 (examination and termination at PND 13 is indicated in current OECD test guideline, adopted in 2016). Importantly, there were no pups at all produced by animals in the high dose group treated with 300 mg/kg bw/day.

Tucker et al. 2018 study

The earliest stages of mammary gland development in late gestation and just prior and after birth have been reported as susceptible time windows for effects of endocrine disruptors (Tucker et al. 2018 and references therein). Tucker et al. investigated the effects of BPAF on development and long-term health of the mammary gland in female CD-1 mice. Pregnant dams were gavaged twice daily with BPAF 0.05 mg/kg bw (n=10), 0.5 mg/kg bw (n=11) or 5 mg/kg bw (n=11) from GD 10.5 (prior to formation of the rudimental mammary epithelial bud) until GD 17.5. Female offspring were followed for up to 16 months.

Table 23: Pubertal mammary gland development score^a for female offspring exposed to BPAF in utero, Tucker et al. 2018

Dose levels (mg/kg bw twice/day)	0	0.05	0.5	5
PND 20	2.03 ± 0.07	2.77 ± 0.27**	2.79 ± 0.19***	2.80 ± 0.17***
PND 28	2.33 ± 0.18	2.79 ± 0.33	2.57 ± 0.18	3.25 ± 0.23*
PND 35	1.92 ± 0.21	3.12 ± 0.35 *	1.96 ± 0.18 ^b	3.05 ± 0.46*
PND 56	2.39 ± 0.15	2.95 ± 0.17	2.78 ± 0.28	2.93 ± 0.37

^aPubertal mammary gland development scores were calculated for female offspring exposed in utero. Scoring: 1=poor development and 4=best development. Scores were based on lateral and longitudinal epithelial growth, presence or absence of terminal end buds (TEB), branching density, budding and appearance of ductal ends. Significantly different from control group: *p<0.05, **p<0.01, ***p<0.001.^bMean body weight was significantly smaller compared to controls.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Mammary glands of females treated in utero with BPAF exhibited greater longitudinal growth (mm) and branching density, higher terminal end buds (TEB) counts and more TEBs/mm². These findings indicate accelerated mammary gland development during puberty in offspring exposed in utero. Table 23 shows significantly higher mammary gland development scores for female offspring at PND 20-35, compared to control offspring. Measurements done at PND 56 demonstrated no statistical differences between the groups, and the control group seemed to have caught up the accelerated growth and development.

Table 24: Histopathological findings - mammary gland lesion incidences, Tucker et al. 2018

Dose levels (mg/kg bw twice/ day)	0	0.05	0.5	5
3 months, no. of animals	n=8	n=9	n=8	n=7
Inflammation, mixed cell	1	1	1	2
8 months, no. of animals	n=5	n=7	n=5	n=6
Lubuloalveolar hyperplasia	0	0	0	0
Inflammation, mixed cell	0	0	0	1
Squamous metaplasia, ductal	0	0	0	1
14 months, no. of animals	n=13	n=14	n=18	n=22
Carcinoma	0	0	0	0
Fibroadenoma	0	0	0	0
Histiocytic sarcoma	0	0	0	0
Lipoma	0	0	0	1
Cyst	0	0	0	3* (14%)
Duct dilation	0	0	0	0
Hemorrhage, focally extensive	0	0	0	0
Inflammation, lymphoplasmacytic perivascular	2	7	7	5
Inflammation, mixed cell	1	1	2	8** (36%)
Inflammation, neutrophilic	0	0	0	1
Inflammation, not specified	0	0	0	1
Keratin	0	1	0	1
Lobuloalveolar hyperplasia	0	0	1	5** (23%)
Lymph node: inflammation neutrophilic	0	0	0	0
Lymph node: Inflammation, mixed with eosinophilic crystals	0	0	0	0
Lymph node: Squamous cell carcinoma or met from Zymbal's gland	0	0	0	1
Lymph node: vascular angiectasis	0	0	0	0
Lymph node: increased cellularity, plasma cells	0	0	0	1

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Papillary hyperplasia, multifocal	0	0	0	0
Squamous metaplasia, ductal	0	1	2	7** (32%)

*Significant trend P<0.05 ** Significant trend P<0.01

By 14 months of age, there was a significant dose-related increase in diagnoses of non-neoplastic lesions development in BPAF-exposed groups. This included cysts, inflammation, lobuloalveolar hyperplasia and squamous metaplasia (Table 24). In one BPAF-treated high dose animal (5 mg/kg), a squamous cell carcinoma was found in the mammary gland.

Prior to vaginal opening at PND 20, the mean serum estradiol concentration of female offspring of all BPAF-treated animals were significantly higher than the levels of control animals. In the high dose group the progesterone levels were also higher compared to controls. Testosterone levels were lower compared to control animals in offspring treated in utero with BPAF 0.05 mg/kg (at PND 28 and PND 35). Later in life hormone levels in serum normalised.

This study indicates accelerated mammary gland development during early puberty after BPAF exposure in utero, an effect that persisted into adulthood. Other indicators of puberty, such as timing of vaginal opening, age at first estrus or estrous cyclicity were not affected.

This study is considered as supporting, since findings in this study points to effects on development of the offspring but are not sufficient for classification. Moreover, the robustness of this study is limited due to poor reporting.

Li et al. study 2016

Li et al. studied effects on gestational and lactational exposure to BPAF on male offspring (daily exposure of maternal Sprague Dawley rats of 0 or 100 mg/kg on GD 3-19 and PND 3-19). The study was a cross-fostering study (GD 3-19: 2 control groups and 2 treatment groups, PND 3-19: unexposed controls (CC) pups exposed prenatally (TC), pups exposed postnatally (CT) and pups exposed both pre- and postnatally (TT)).

Gestational and lactational exposure of BPAF resulted in significantly increased levels of free and total BPAF in both serum and in testis, compared to the control group. These results show that BPAF was transferred via cord blood and breast milk, although BPAF concentrations were not measured directly in these body fluids. Gestational and lactational exposure lead to significantly decreased Inhibin B levels in serum and in testis of male offspring, compared to controls. Testosterone levels in serum and testis were increased in all treatment groups compared to controls, but only significantly increased in the TT group (no data available, results are shown in bar charts). Estradiol, luteinizing hormone and follicle-stimulating hormone levels in serum did not differ between the four groups, except that estradiol levels in CT and TC groups were significantly lower than in the TT group. Furthermore, androgen receptor levels in testes increased following BPAF exposure.

Maternal weights of treated animals were significantly lower compared to controls, when measured at GD 12, GD 15 and GD 19 (no data available, results are shown in bar chart). However, no significant differences related to litter size, birth weight, sex ratio and survival rate of pups were found between control and treated groups. Offspring exposed to BPAF during lactation (CT) had significantly lower body weight compared to controls, at PND 12, PND 18 and PND 23 (no data available, results are shown in bar charts). The body weight of offspring exposed during both gestation and lactation was also significantly lower at PND 6, PND 12 and PND 16, compared to controls. No differences between the groups were seen for absolute and relative weights of the testis and epididymes.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4- HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

This study is considered as supporting, since findings in this study points to effects on development of the offspring but are not sufficient for classification. Moreover, the robustness of this study is limited due to poor reporting since results were mainly shown in bar charts.

Gong et al. 2017

In a non-guideline *in vivo* study, male and female adolescent offspring exposed *in utero* to BPAF was examined using several behaviour tests. Pregnant female mice were treated with 0, 0.4 and 4 mg/kg BPAF per day from GD 1 to GD 19. Different behavioural tests were performed from PND 35 to PND 42 including an Open field test, a Novelty-suppressed feeding test, a Sucrose preference test, a Tail suspension test, a Forced swimming test, a Novel object recognition task and a Contextual fear conditioning test. Test results indicate that maternal BPAF exposure could induce anxiety- and depressive-like behaviors in male mice. Furthermore, this study indicates that BPAF exposure *in utero* could have adverse effects on memory formation in both male and female mice offspring.

This study is considered as supporting, since findings in this study points to effects on development of the offspring but are not sufficient for classification. Moreover, the robustness of this study is limited due to poor reporting.

Summary of available studies

The results from the OECD TG 422 study (GLP compliant) do not indicate adverse effects on offspring. However, no offspring were produced in the highest dose group. The pups were followed until PND 5 and no histopathological investigations were conducted.

There are a few non-guideline studies that show effects on offspring treated during the fetal period. These effects include e.g. abnormal mammary gland development and mammary gland lesions (dose response trends), transfer of BPAF in breast milk during lactation and impact on hormone levels in serum and testes in offspring, and indications of behavioural changes such as anxiety in male mice. These parameters were not assessed in the Study report, 2011. The available data on developmental effects is mainly generated by non-guideline studies, which makes the quality and relevance of results difficult to assess. The studies are considered as supporting, since the findings point to effects on development of the offspring. However, the studies are considered not sufficient for classification, based on methodological deficiencies and due to poor reporting.

In addition to the *in vivo* experimental studies mentioned above, there are several mechanistic studies on the effects of BPAF in zebrafish, and *in vitro* available and listed in Table 11. Results consistently indicate estrogenic and anti-androgenic effects of BPAF, mechanisms of potential relevance for the effects seen on development *in vivo*.

There are currently ongoing studies on BPAF within the National Toxicology Program (NIEHS), which includes a Modified One-Generation (MOG) study. No results are publically available at the time of writing this proposal. However, results generated from the MOG study may be used to clarify this endpoint in the future.

10.10.6 Comparison with the CLP criteria

Since there are no studies on developmental toxicity conducted on the substance benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate data on BPAF has been used as the basis for this CLH proposal. The substance is a 1:1 salts of a BPAF-based anion moiety, and a cation, and thus contains ca 50% BPAF.

In three non-guideline experimental studies in rat and mouse, BPAF was shown to cause effects on development, including effects on development of mammary glands (0.05-5 mg/kg bw, twice/day), impact

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE**

on hormone levels in serum and testes in offspring (100 mg/kg bw/day), and behavioural changes such as anxiety in male mice (0.4-4 mg/kg bw/day). The studies are non-guideline studies, which makes the quality and relevance of results difficult to assess. The studies are considered not robust enough as basis for classification, because of methodological deficiencies and due to poor reporting. The weight of evidence for developmental toxicity is considered weak.

Classification in Repr. 1A is not justified since there is no human data available on BPAF.

Classification in Repr. 1B is not justified since the evidence for developmental toxicity from existing experimental data on BPAF is not considered to be clear evidence.

Classification in Repr. 2 is not justified since the evidence for developmental toxicity based on existing experimental data on BPAF is not conclusive and cannot at present be considered as some evidence.

10.10.7 Adverse effects on or via lactation

Table 25: Summary table of animal studies on effects on or via lactation

Method, guideline, deviations if any, species, strain, sex, no/group	Test substance, dose levels duration of exposure	Results	Reference
<p>Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (oral:gavage) according to GLP.</p> <p>OECD Test Guideline 422</p> <p>Species, strain and sex:Rat (Sprague-Dawley) males and females</p> <p>Treatment groups: 12 males + 12 females per treatment group.</p> <p>Reliability Score 1 according to registrant</p>	<p>Test substance: 2,2-Bis (4-hydroxyphenyl)-hexafluoropropane (BPAF) Purity: 99.69%</p> <p>Dose levels: 0, 30, 100, 300 mg/kg bw/day.</p>	<p>No adverse effects were seen on offspring exposed to BPAF in utero (30 and 100 mg/kg bw/day). However, no offspring was produced in the highest dose group (300 mg/kg bw/day).</p>	<p>Study report, 2011.</p>
<p>Non-guideline study, Cross-fostering study</p> <p>Effects of gestational and lactational exposure to BPAF on male offspring were studied.</p> <p>Reliability Score 4 according to registrant</p>	<p>Test substance: BPAF (purity 97%)</p> <p>Species, strain and sex: Rats: Sprague Dawley females</p> <p>Treatment groups: 30 females per dose group (GD 3-19), 15 females per dose group (PND 3-19).</p> <p>Dose level: 0, 100</p>	<p>Lactational exposure caused significantly increased levels of BPAF in serum and in testis, showing that BPAF was transferred via breast milk. Lactational exposure lead to significantly decreased Inhibin B levels in male offspring. In addition, androgen receptor levels in testes increased following lactational BPAF exposure.</p> <p>Statistically significant decreased body weights in pups exposed via lactation. Maternal body weights of treated females were significantly decreased at GD 12 - GD 19, compared to controls.</p>	<p>Li et al. 2016.</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Method, guideline, deviations if any, species, strain, sex, no/group	Test substance, dose levels of duration of exposure	Results	Reference
	mg/kg/day Duration of exposure: GD 3 to GD 19 and PND 3 to PND 19.		

10.10.7 Short summary and overall relevance of the provided information on effects on or via lactation

Results from the Study report, 2011, do not indicate any effects of BPAF on or via lactation. Pups were followed until PND 5.

In a non-guideline cross-fostering study (Li et al. 2016) BPAF was given to female rats during the lactation, which resulted in transfer of BPAF via breast milk to the pups. Lactational exposure of BPAF resulted in significantly increased levels of BPAF in both serum and in testis. Lactational exposure also lead to significantly decreased Inhibin B levels in serum and in testis of male offspring, compared to controls. Furthermore, androgen receptor levels in testes increased following BPAF exposure. Maternal weights of treated animals were significantly lower compared to controls (estimated by Dossier submitter to be less than 10% based on bar chart), when measured at GD 12, GD 15 and GD 19. Offspring exposed to BPAF during lactation also demonstrated significantly lower body weight compared to controls.

This non-guideline study is not considered robust enough as basis for classification due to poor reporting. The registrant has assigned the study a reliability score of 4. It is not possible to draw conclusions on adverse effects via lactation based on these findings.

10.10.8 Comparison with the CLP criteria

Since there are no studies on effects on or via lactation conducted on the substance benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate data on BPAF has been used as the basis for this CLH proposal. The substance is a 1:1 salts of a BPAF-based anion moiety, and a cation, and thus contains ca 50% BPAF.

Since no conclusive data are available, comparison with the CLP criteria is inapplicable.

According to CLP Annex I classification of substances for effects on or via lactation can be assigned on the:

- (a) human evidence indicating a hazard to babies during the lactation period; and/or
- (b) results of one or two generation studies in animals which provide clear evidence of adverse effect in the offspring due to transfer in the milk or adverse effect on the quality of the milk; and/or
- (c) absorption, metabolism, distribution and excretion studies that indicate the likelihood that the substance is present in potentially toxic levels in breast milk.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

10.10.9 Conclusion on classification and labelling for reproductive toxicity

Classification of benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate for adverse effects on sexual function and fertility is warranted: Repr. 1B H360F. A specific concentration limit for adverse effects on sexual function and fertility is not considered justified since the estimated ED10 value is within the medium potency group (4 mg/kg bw/day < ED10 value < 400 mg/kg bw/day).

RAC evaluation of reproductive toxicity

Summary of the Dossier Submitter's proposal

The DS used data on the constituent BPAF as the basis for this CLH proposal, as BDDP-BPAF is a salt of a BPAF-based anion moiety and contains approximately 50% BPAF.

Adverse effects on sexual function and fertility

The DS evaluated adverse effects on sexual function and fertility of BDDP-BPAF mainly based on a screening study with BPAF in rats performed according to OECD TG 422 and a 28-day study in rats with BPAF performed according to OECD TG 407, both using the oral route of exposure. Supporting information in the form of a Uterotrophic assay and a Hershberger assay, as well as several mechanistic studies, were also included in the proposal. The DS proposed classification for adverse effects on sexual function and fertility in category 1B (Repr. 1B; H360F).

In the OECD TG 422 screening study (0, 30, 100, 300 mg/kg bw/d BPAF, purity 99.69%), treatment-related effects on sexual function and fertility in females included irregular oestrus cycles, dose-dependent increases in the incidence of non-pregnant females with a fertility index down to 0% for the high dose females (300 mg/kg bw/d). The pre-implantation losses were non-significantly higher in mid dose animals compared to controls; however, there were large individual variations. The implantation index was lower in treated mid dose females, and total litter loss was observed in one female each of the low (30 mg/kg bw/d) and mid dose (100 mg/kg bw/d) groups. A higher incidence of follicular/fluid-filled cysts in the ovaries, minimal glandular hyperplasia of the mammary gland, and epithelial hyperplasia of the vagina was seen in high dose females (300 mg/kg bw/d). A direct comparison to the control group however was compromised due to 0% pregnancy in the high dose. In males, adverse effects on number of spermatozoa, significant reductions in absolute and relative epididymis and absolute testes weights in the high dose males, as well as a significantly and dose-dependently reduced secretory content in the prostate and of the seminal vesicles, were seen in treated animals. Leydig cell atrophy was noted in mid and high dose males alongside tubule-alveolar differentiation of the mammary glands at the high dose. General toxicity was not marked according to the DS, concluding that a clear effect of BPAF on sexual function and fertility was evident as pregnancy incidences were reduced at all doses.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

In the OECD TG 407, 28-day study (0, 10, 30, 100 mg/kg bw/d), significantly lower absolute weights of reproductive organs were observed in BPAF treated males, including absolute weights of prostate, ventral prostate, and seminal vesicles. Furthermore, atrophy of testicular Leydig cells, and of the mammary glands noted in males, as well as irregularities observed in the females' oestrous cycles indicated endocrine-mediated (oestrogenic) mechanisms underlying the toxicity of BPAF.

BPAF (0, 50, 200, 600 mg/kg bw/d) tested positive in the Uterotrophic assay with a clear dose-response and significantly increased uterine blotted weight at all doses tested, suggesting oestrogen agonistic properties of BPAF.

In the Hershberger assay the relative glans penis weight increased significantly in rats at the high dose. However, due to general toxicity and considerable variability in the controls, an androgen agonistic property could not be verified according to the study authors.

Several mechanistic studies on the effects of BPAF in zebrafish and mammalian cells *in vitro* were available and results consistently indicated oestrogenic and anti-androgenic effects of BPAF, mechanisms were considered relevant for the effects seen on fertility *in vivo*.

The DS further highlighted that the structurally similar BPA has a harmonised classification as Repr. 1B (H360F) affecting the reproductive system similarly but not as potently as BPAF.

In a weight of evidence approach, the DS concluded that the available data provided clear evidence of adverse effects on both male and female sexual function and fertility, that there was no mechanistic information indicating that the observed effects were not relevant for humans, and that classification of BPAF, and thus BDDP-BPAF, as Repr. 1B; H360F is warranted.

Adverse effects on the development of the offspring

The DS evaluated the developmental toxicity of BDDP-BPAF mainly based on the OECD TG 422 screening study in rats with BPAF, as well as on a few non-guideline studies with BPAF, which were identified during a literature search. The DS proposed no classification for effects on development. The DS highlighted that the National Toxicology Program (NIEHS) currently performs a Modified One-Generation (MOG) study with BPAF.

In the OECD TG 422 study, no pups at all were produced by the parental animals treated with 300 mg/kg bw/d. Otherwise, no significant effects of BPAF on *in utero* treated offspring were observed. Post-implantation loss was higher in the mid dose group, but this effect was statistically not significant. Viability index and percentages of live births were not affected. No differences in sex ratio and body weights of offspring of treated and control animals were noted. No evident effects from BPAF treatment were noted during necropsy. The DS reported that pups were examined only until PND 5, although examination and termination at PND 13 was indicated in the current OECD TG 422 (adopted in 2016).

There were a few recent non-guideline studies that reported effects on offspring following

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

treatment of dams with BPAF during the foetal period. These effects included, among others, accelerated mammary gland development and mammary gland lesions (trends in dose-response) in female offspring, transfer of BPAF via breast milk during lactation, and an impact on testosterone serum levels and androgen receptor levels in testes of male offspring. Increased anxiety- and depressive-like behaviours in male adolescent offspring after foetal BPAF treatment were reported in another study. The DS noted that these parameters were not assessed in the OECD TG 422 study.

The DS concluded that there is a concern for developmental toxicity, but the available studies from the scientific literature (non-guideline, non-GLP) were considered not robust enough as a basis for classification due to methodological deficiencies and poor reporting. The weight of evidence for developmental toxicity was thus considered weak and no classification for developmental toxicity was proposed.

Adverse effects on or via lactation

The DS evaluated the effects of BDDP-BPAF via lactation mainly based on the OECD TG 422 screening study in rats with BPAF, as well as on a non-guideline cross-fostering study with BPAF identified during the literature search. Toxicokinetic information was also included in the CLH report.

Results of the OECD TG 422 study did not indicate any effect of BPAF on or via lactation. However, in this study pups were only observed until PND 5. In a non-guideline cross-fostering study (assigned Klimisch 4), BPAF was given to female rats during lactation. BPAF was transferred via breast milk to the pups. The lactational exposure resulted in significantly increased levels (free and total) of BPAF and significantly decreased Inhibin B levels in both serum and testes of male offspring, and in increased androgen receptor levels in testes. Maternal weights of BPAF-treated dams were significantly lower at several gestational days (GDs) and the offspring that was exposed during lactation also had significantly lower bw compared to controls.

The DS considered the available data not sufficiently robust for classification due to poor reporting, and that no conclusions could be drawn regarding classification for adverse effects on or via lactation.

Comments received during standard consultation

Three Member State Competent Authorities (MSCAs) submitted comments on the CLH proposal during the consultation. No comments from stakeholders were received. All commenting MSCAs supported the proposed classification of BDDP-BPAF as Repr. 1B; H360F based on read across from BPAF, as the substance contains ca. 50% of BPAF as an anion.

Assessment and comparison with the classification criteria

Adverse effects on sexual function and fertility

The DS included a screening study in rats performed according to OECD TG 422 and a 28-

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

day study in rats performed according to OECD TG 407 (both GLP-compliant and rated Klimisch 2 and 1, respectively, by the registrant(s)), both with BPAF and both using the oral administration route for the test substance, for the assessment of sexual function and fertility. Supporting information from a Uterotrophic assay and a Hershberger assay as well as several mechanistic studies were available. Most of the provided studies indicated adverse effects of BPAF on male and female sexual function and fertility.

OECD TG 422

In an OECD TG 422 study, BPAF was administered by gavage to SD rats (males for 42 days, females for 55 days, including a 2-week maturation phase, pairing, gestation and early lactation for females), at 0, 30, 100 and 300 mg/kg bw/d for control, low, mid, and high dose, respectively. Two recovery groups (5/sex/group, high dose and control) were treated for 42 days with a subsequent post-exposure observation period of 14 days. Recovery animals were not mated. Regarding study reliability, it was indicated in the REACH registration dossier that the exposure duration in males was not consistent with the guideline requirements for repeated dose toxicity, which restricted the reliability of the endpoint for males only. Furthermore, it was noted by the DS that pups were examined only until PND 5, although examination and termination at PND 13 was indicated in the current OECD TG 422.

Mating performance and pregnancy outcomes

The number of pairing days until mating was not affected by treatment with BPAF and the mating index did not differ significantly between controls and treated animals (91% in high dose animals vs. 92% in controls). Irregular oestrous cycles were observed in 2/11 (18%) high dose animals. At this dose, one animal with continuous anoestrus interval was reported to fail to mate, and another female that showed extended oestrus, was reported to not become pregnant. One female of the 100 mg/kg bw/d treatment group (1/12) and one control female (1/12) did not mate either.

Notably, exposure to BPAF had a clear impact on the pregnancy outcomes, as no pregnancy was induced in any of the high dose females that were mated (10/11 mated animals, 1/11 animal pair did not mate). The incidence of females that mated successfully but did not become pregnant increased with increasing dose (0/11, 2/12, 3/11 and 10/10 for controls, low, mid and high dose, respectively). The fertility index was 100%, 83%, 64% and 0% for the controls, low, mid, and high dose, respectively. Pre-implantation losses were slightly higher in the mid dose animals compared to the controls (19%±17 vs. 12%±13), but this effect was not statistically significant. The number of corpora lutea and implantations were reported to be lower in the treated females compared to the controls (corpora lutea: 16.7±3.6, 14.7±5.8, 14.0±7.8 for control, low, mid dose; implantations: 14.1±1.9, 12.1±3.8, 10.4±4.8 for control, low, mid dose); however, these effects were not statistically significant either. In line with these findings, the implantation index was lower for the mid dose with 81% vs. 88% in control females. RAC notes that there are discrepancies within the treatment groups between the number of pregnant females and the number of females investigated for corpora lutea, implantation sites, pre- and post-implantation loss, as well as for implantation index. In the original study report, for some treated females the individual data for these parameters are missing, although these females were reported to have given birth to offspring. No justification was provided for the missing values. Before the RAC plenary, the REACH registrants were

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

asked to clarify the issue regarding the missing values for the abovementioned parameters. In response, the registrants stated that they were not the original study monitors and that the study sponsor was the Japanese Ministry of Economy, Trade and Industry (METI), which was why they could not give any specific explanation or reasoning but could only speculate. Accordingly, RAC considers that the comparison of these parameters to the controls is compromised, which is why analysis of the impact of BPAF on these parameters is essentially hampered. The study author concluded that for these parameters, no statistically significant effect was observed.

Total litter loss was observed for one female each of the low dose (1/10 = 10%) and mid dose (1/8 = 13%) group, compared to none among control females. Gestation index was dose-dependently affected by treatment (100%, 90% and 88% for controls, low and mid dose females, respectively); however, these effects were reported to be not statistically significant.

Table: Fertility parameters

Dose levels (mg/kg bw/d)	0	30	100	300
No. of pairs examined	12	12	12	11 [#]
Oestrous cycle (days)	4.0 ± 0.0	3.9 ± 0.2	4.3 ± 0.4	4.2 ± 0.2
Irregular oestrous cycle	0/12	0/12	0/12 ^{##}	2/11 (18%)
No. of pairs with successful mating	11	12	11	10
Mating index (%) = (No. of pairs with successful mating/No. of pairs examined) x 100	91.7	100.0	91.7	90.9
No. of pregnant females	11	10	8	0
Fertility index (%) = (No. of pregnant animals/No. of pairs with successful mating) x 100	100	83.3	63.6	0
Pairing days until mating	3.9 ± 3.5	2.3 ± 1.3	2.4 ± 1.4	4.0 ± 4.1
No. of oestrous stages without mating	0.0 ± 0.0	0.0 ± 0.0	0.6 ± 1.2	0.9 ± 1.3
Total litter loss <i>in utero</i>	0	1 of 10 (10%)	1 of 8 (13%)	-
Gestation Index (%) = (No. of females with live born pups/No. of pregnant females) x 100	100	90	87.5	-
Gestation length (days)	22.9 ± 0.6	23.0 ± 0.6	22.9 ± 0.2	-
No. of corpora lutea	16.7 ± 3.6 (n=11)	14.7 ± 5.8 (n=9)	14.0 ± 7.8 (n=7) ^{###}	-
No. of implantation sites	14.1 ± 1.9 (n=10)	12.1 ± 3.8 (n=7) ^{###}	10.4 ± 4.8 (n=7) ^{###}	-
Pre-implantation loss ((No. of corpora lutea - No. of implantation sites)/No. of corpora lutea) x 100 (mean %)	11.9 ± 13.2 (n=10)	10.6 ± 18.2 (n=7) ^{###}	18.7 ± 16.8 (n=7) ^{###}	-
Implantation index = (No. of implantation sites/No. of corpora lutea) x 100 (mean %)	88.1 ± 13.2 (n=10)	89.4 ± 18.2 (n=7) ^{###}	81.3 ± 16.8 (n=7) ^{###}	-
Post-implantation loss ((No. of implantation sites - Total no. of offspring born)/No. of implantation sites) x 100 (mean %)	9.5 ± 10.3 (n=10)	7.8 ± 7.6 (n=7) ^{###}	22.9 ± 35.5 (n=7) ^{###}	-
Females with live offspring (no.)	11	9	7	-
Delivery index = (No. of pups delivered/No. of implantation sites) x 100	90.5 ± 10.3	92.2 ± 7.6	77.1 ± 35.5	-
No. of females rearing young to day 5 of age	11	9	7	0

One high dose female failed to mate.

in CLH report: 1/12; corrected value after study report access

No justification is provided in the study report as to why the number of females for the parameter number

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

of implantation sites, pre-/post-implantation loss and implantation index is n=7 instead of n=9. The numbers are missing in the individual tabled data. Data on number of corpora lutea are also missing for one of these 2 females. Individual tabled data further indicates that the very same 2 females, for which this information is missing, gave birth to offspring.

No justification is provided in the study report as to why the number of females for the parameters corpora lutea, number of implantation sites, pre-/post-implantation loss and implantation index is n=7 instead of n=8. The numbers are missing in the individual tabled data. Individual tabled data further indicates that the very same female, for which this information is missing, gave birth to offspring.

Only limited information on historical control data (HCD) was given in the study report (see the table below). Data as to July 2007 on values for the group mean (plus 2 standard deviations) were reported for a limited number of animals. As the TG 422 study was conducted in 2009/10, the quality of the HCD is very limited and no information was given on the source of it. Before the RAC plenary, the registrants were asked to clarify the issue regarding the relevance of the historical control data. In response, the registrants stated that they were not the original study monitors and that the study sponsor was the Japanese Ministry of Economy, Trade and Industry (METI), which is why they could not provide any further relevant information.

Table: Historical control data (range = mean \pm 2 standard deviations; values in brackets indicate group mean and standard deviation, respectively)

	Range	No. of animals
Gestation length (days)	21.0 (22.2) - 23.4 (0.6)	85
No. of corpora lutea	14 (18) - 22 (2)	72
No. of implantation sites	12 (16) - 19 (2)	73
Pre-implantation loss (%)	2 (12) - 22 (5)	55
Post-implantation loss (%)	3 (7) - 11 (2)	31

Female reproductive organs

Minimal glandular hyperplasia of the mammary gland was seen in 4/11 (36%) non-pregnant females of the high dose group, which might suggest a treatment-related (endocrine) effect, but was not seen in the recovery control or 300 mg/kg bw/d (non-mated) females at study observation end. Also, a direct control for non-pregnant females was missing as only one individual did not mate in the control group. Historical control data was not provided in the dossier. Ovarian cysts were found in several of the non-pregnant females of each treatment group. Follicular/fluid-filled cysts appear to be dose-dependently increased (although there is no directly comparable control), 9/11 high dose females (82%) had follicular/fluid-filled cysts on the ovaries, an effect that was absent in the one non-pregnant control female (0/1, 0/2 (0%), 2/4 (50%), 9/1 (82%) for control, low, mid and high dose, respectively). This could be a treatment-related effect, the interpretation is supported by the observation of follicular cysts seen in the treated recovery females (4/5 or 80%) versus recovery controls (0/5) suggesting that the effect is treatment related and did not regress during recovery. Effects of uterus/cervix and vagina (dilatation horn, endometrial gland proliferation and keratinisation cervix and epithelial hyperplasia, epithelial keratinisation and keratin cysts, respectively) were observed in a few non-pregnant female animals of all dose groups, but not in the single non-pregnant control female. Even though only one individual did not mate in the control group, no dose-response can be inferred for the treatment groups. The study author rated this finding as normal cyclical changes in the female rat and that there was no convincing effect of the treatment in this study. Epithelial hyperplasia of the vagina was seen in 4/11 (36%) of the non-pregnant high dose females compared to none in the other

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

dose groups. However, this effect was described as minimal. Again, the study author, allowing for normal cyclical changes, considered there was insufficient evidence to suggest an effect of treatment.

Table: Number of female animals with histopathological findings in reproductive-related organs, only females that failed to mate/non-pregnant*

Dose levels (mg/kg bw/d)	0	30	100	300
No. of animals	n=1	n=2	n= 4	n= 11
No. animals that failed to mate	1/12 (8%)	0	1/12 (8%)	1/11 (9%)
No. of animals not pregnant	0	2/12 (16%)	3/12 (25%)	10/11 (90%)
Mammary gland				
Glandular hyperplasia (minimal)	0	0	0	4/11 (36%)
Ovaries				
Cystic corpora lutea	0	1/2 (50%)	1/4 (25%)	3/11 (27%)
Follicular/fluid-filled cyst	0	0	2/4 (50%)	9/11 (82%)
Haemorrhagic cyst	0	0	0	1/11 (9%)
Vacuolation stroma	0	0	0	2/11 (18%)
Thyroid				
Follicular cell hypertrophy (minimal)	0	1/2 (50%)	0	5/11 (45%)
Uterus/Cervix				
Dilatation horn 1				
Minimal	0	0	1/4 (25%)	1/11 (9%)
Slight	0	1/2 (50%)	1/4 (25%)	1/11 (9%)
Dilatation horn 2				
Minimal	0	0	2/4 (50%)	1/11 (9%)
Slight	0	1/2 (50%)	0	1/11 (9%)
Endometrial gland proliferation	0	0	0	1/11 (9%)
Keratinisation cervix	0	2/2 (100%)	3/4 (75%)	1/11 (9%)
Vagina				
Epithelial hyperplasia				
Minimal	0	0	0	4/11 (36%)
Epithelial keratinisation	0	2/2 (100%)	1/4 (25%)	2/11 (18%)
Keratin cyst	0	0	0	1/11 (9%)

*No HCD available

Male reproductive organs

Treatment-related effects on sexual function and fertility in males included adverse effects on no. of spermatozoa. Sperm reading scores (based on number of sperm detected) in high dose males were 0 (n=1), +1 (n=3), +2 (n=1) and +3 (n=5) compared to control males which all had scores of +3 (n=11) (score 1+: few spermatozoa present, score 2+: continuous few spermatozoa in all fields, and score 3+: many spermatozoa in all fields). Moreover, significant reductions in absolute epididymis and testes weights in the high dose males compared to controls (-20% and -11%, respectively) were recorded. Similarly, relative epididymis weight was significantly lower (-13%) in high dose males, whereas relative testis weight was not affected. A significant and clearly dose-dependent reduction in secretory content of the prostate, indicated by smaller organ size, was seen in treated animals (up to 8/12 (67%) in high dose males; 4/5 (80%) in high dose recovery males; none in respective controls). In addition, significantly and dose-dependently reduced secretory content of seminal vesicles was reported for all BPAF treatment groups with 100% males affected in the high dose (main study: 12/12 (100%) vs. 1/11 (8%) in controls; recovery group: 3/5 (60%) at high dose vs. 0/5 (0%) in

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

controls); thus, the recovery groups did indicate a trend but no convincing regression of these changes. Leydig cell atrophy was present in 1/12 (8%), 0/12 (0%), 3/12 (25%), 11/12 (92%) control, low, mid and high dose males, respectively, thus dose-dependently increased. This is considered a treatment-related effect. This effect was visible in 1/5 treated recovery males vs. 0 males in recovery controls. The lower rate of 20% after recovery (instead of 92% seen in high dose males) may indicate a trend for regression. However, the treated recovery group was small. Overall, an impact on endocrine status in males is suggested. Decreased weight of seminal vesicles and ventral prostate in rats is a relatively sensitive indicator of reduced androgen levels, also supported by the observed Leydig cell atrophy. The moderate to severe atrophy of testes reported for 2/5 high dose recovery males cannot be excluded as being a treatment-related effect by RAC. However, as no other treatment or control group displayed such change a relation to treatment appears uncertain. Again, HCD was not presented.

Tubuloalveolar differentiation of mammary glands was observed dose-dependently in males with increasing severity and incidence. 50% high dose males (6/12) showed this effect (slight to moderate in severity), while still 4/5 high dose recovery males were affected at termination. Thus, a regression of this effect was not evident. No controls had a slight to moderate severity of this effect, but 3/12 (25%) control males exhibited minimal tubuloalveolar differentiation of mammary glands.

Table: Number of male animals with histopathological findings in reproductive-related organs. Incidence in percent in parenthesis*

Dose levels (mg/kg bw/d)	0	30	100	300	Recovery 0	Recovery 300
No. of animals	n = 12	n = 12	n = 12	n = 12	n= 5	n= 5
Mammary gland - Tubuloalveolar differentiation						
No section	2	2	2	3	0	0
Absent	7	4	3	1	5	1
Minimal	3 (25%)	4 (33%)	6 (50%)	2 (17%)	0	0
Slight	0	2 (17%)	1 (8%)	4 (33%)	0	1 (20%)
Moderate	0	0	0	2 (17%)	0	3 (60%)
Prostate - Reduced secretory content						
No section	0	0	1	0	0	0
Absent	23	11	7	4	5	1
Present	0	1 (8%)	4 (33%)	8 (67%)	0	4 (80%)
Seminal vesicles - Reduced secretory content						
Vesicle 1						
No section	0	0	1	0	0	0
Absent	11	10	5	0	5	2
Present	1 (8%)	2 (16%)	6 (50%)	12 (100%)	0	3 (60%)
Vesicle 2						
No section	0	0	1	0	5	5
Absent	11	10	6	0	0	0
Present	1 (8%)	2 (16%)	5 (42%)	12 (100%)	0	0
Testes - Atrophy						
Testis 1						
Absent	12	12	12	12	5	3
Moderate	0	0	0	0	0	1 (20%)
Severe	0	0	0	0	0	1 (20%)
Testis 2						
Absent	12	12	12	12	5	4
Severe	0	0	0	0	0	1 (20%)

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Leydig cell (atrophy**)						
Absent	11	12	9	1	5	4
Present	1 (8%)	0	3 (25%)	11 (92%)	0	1 (20%)

*No HCD data available

**Leydig cell atrophy is commonly a result of Leydig cell necrosis or apoptosis and subsequent loss of Leydig cells. No further information was given in the report.

General toxicity

One female (1/12) treated with 300 mg/kg bw/d had to be killed *in extremis* on Day 6 following severe clinical signs, which were attributed to an error in the administration of the test material formulation.

Clinical signs included increased salivation and staining around the mouth post-dosing for animals in all treatment groups in a dose-response manner. Dehydration and staining around the anogenital region was observed for two high dose females. One high dose female, which was killed on Day 6, demonstrated severe clinical signs that were considered to be caused by incorrect administration of the test substance. There were no effects observed related to behaviour, functional performance or sensory reactivity in any of the treated groups. Mean body weights showed no significant and treatment-related changes in males. The DS reported a tendency towards lower bw among animals of the mid and high dose compared to controls; however, due to the lack of reporting of standard deviations, median values and/or confidence intervals for bw, it is premature to interpret the differences in the given mean values as potential treatment effect. In high dose recovery males, however, significantly lower mean bw were reported from day 15 until the end of the experiment (range: -13% at day 15 up to -22% at day 43). Two weeks post-exposure, bw of high dose males (recovery group) was still significantly lower compared to controls (-17%). It is noted that recovery control males generally had a higher mean bw than non-recovery control males. Despite slight body weight gain changes, there were no significant differences on mean body weights among females in the different dose groups during maturation. A significantly lower mean body weight (-10%) was observed for low dose females at GD 20 (however, no dose-response was evident during gestation), during lactation (day 0 and 4) for both the low and mid dose females (range: 7 to 10%).

Mean food consumption for males was significantly lower in the two highest dose groups (-9% and -22%, respectively) during the first week of treatment. Water consumption was significantly higher among all groups of treated males at all assessment points (change for high dose males +19% to +39% compared to controls). Treated high dose females also demonstrated significantly lower food consumption during maturation week 1 (-19% mid dose and -25% high dose). At GD 7-14 and GD 14-20, females had a lower food intake (low and mid dose (-13%) on GD 7-14 and the mid dose (-11%) on GD 14-20,). No high dose females (non-pregnant) were included in comparative evaluations after maturation and mating weeks. As for males, water consumption increased significantly during pre-mating days 1-7 (mid dose +30% and high dose +39%), and during days 8-14 (high dose group +11%).

Some changes in haematology and blood chemistry were reported, including significant reductions in Hb and RBC (-8% and -9%, respectively, prior termination day 42) in high dose males, significant higher ALAT values in mid and high dose males (+ 35-37%, day 42), and significantly higher ALAT value (+ 74%) for high dose females during the

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

maturation phase (day 14).

Regarding organ weights, mean relative weights of adrenals and liver were significantly higher in high dose males (+25% and +10%, respectively), while in recovery high dose males the mean absolute liver weight was significantly lower compared to control animals (-18%). In treated recovery males, relative organ weights for adrenal, brain, spleen and thymus were significantly higher as well when compared to controls. For females, relative brain weights in the low and mid dose groups were significantly higher compared to controls (+7% and +9%, respectively). The mean absolute heart weights were significantly lower in the low (-17%) and mid dose (-15%) females compared to controls. Non-pregnant females in the high dose group were not included in comparative evaluations after maturation and mating.

RAC conclusion

RAC concludes that clear treatment-related dose-dependent effects of BPAF on fertility were observed with no pregnancies achieved at the top dose of 300 mg/kg bw/d (0% fertility index) and fewer pregnancies at the low and mid dose of 30 and 100 mg/kg bw/d, respectively. Some indications of general toxicity were noted in the mid and high dose animals; however, the effects were rather of mild to moderate nature and RAC considers that the general toxicity was not marked. Some effects on food consumption and bw development were seen in male high dose animals, but no consistent effect was noted in high dose pregnant females or non-pregnant females of the recovery group. Therefore, the observed effects on male and female sexual function and fertility are not considered to be a secondary non-specific consequence of parental systemic toxicity. Uncertainties with respect to effects on corpora lutea, number of implantation sites, pre-/post-implantation loss and implantation index, were noted by RAC, not allowing a firm conclusion on these parameters. However, effects of BPAF on fertility (no. of pregnant females) are considered as unequivocal substance-related effects justifying classification.

OECD TG 407

Supporting evidence comes from a 28-day repeated-dose toxicity study conducted according to OECD TG 407 (*in vivo* screening tests to detect endocrine-mediated effects) using Crj:CD rats. Rats were given 0, 10, 30 and 100 mg/kg bw/d BPAF by oral gavage, for 28 days, and each dose group comprised 10 males and 10 females.

Reproductive organs and histopathology

For high dose males, absolute weights of prostate, ventral prostate, and seminal vesicle were significantly lower (-23%, -25%, and -28%, respectively), and histopathological findings demonstrated significant atrophy of testicular Leydig cells in treated males. RAC notes that this is well in line with the OECD TG 422 study results. Atrophy of the mammary glands was also seen in 3/10 high dose males, compared to none in the other groups. Although, this effect was not statistically significant, it might be indicative of an endocrine-mediated effect. No adverse effects on sperm were reported. In females, no histopathological effects on reproductive organs were observed, while irregular oestrous cycles were reported. No details were included in the CLH report, whereas in the REACH registration dossier, irregular oestrous in the 30 and 100 mg/kg bw/d groups, and the dioestrous stage continued in some animals were reported. The mean duration of oestrous cycles was prolonged in the study at high dose, however without statistical significance (control: 4.2±0.4 days, 100 mg/kg bw/d: 4.9±0.9 days). Oestrous cycling

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

days could not be measured in 1/10 and 3/10 rats of the mid (30 mg/kg bw/d) and high dose (100 mg/kg bw/d), respectively, due to irregularity of their oestrous cycles.

General toxicity

Terminal body weights in high dose males were significantly lower (-12%) compared to controls. In mid and high dose females, mean bw was significantly lower compared to controls (-7% and -8%, respectively). The effect was reported to be accompanied by decreased food consumption.

Regarding blood chemistry and haematology, in high dose males white blood cell counts (WBC), total cholesterol levels, as well as albumin values were significantly lower, and serum T4 levels were significantly higher compared to controls (+28%). In high dose females, cholinesterase and total cholesterol values were lower when compared to controls, whereas total bilirubin was higher. As with males, serum T4 levels were significantly higher in those animals than in controls (+53%).

Organ weight measurements revealed significantly higher relative kidney (+9%), adrenals (+23%) and brain (+15%) weights in high dose males, whereas absolute weights of liver (-18%), heart (-12%) and spleen (-17%) were significantly lower in these animals. Histopathological examination revealed significant hypertrophy of the adrenal zona fasciculata (8/10 vs. 1/10), and decreased hepatocytic glycogen (8/10 vs. 1/10) when compared to controls. Among high dose females, the absolute heart weight was significantly lower (-10%) and the relative brain weight was higher (+8%). It seems, however, that in females only these two organs were weighed, while no values were presented for any other organ.

Table: Significant histopathological findings in male rats (Umano *et al.*, 2012)

Dose levels (mg/kg bw/d)	0	10	30	100
Animals per group	10	10	10	10
Testis: atrophy of Leydig cells	0	0	0	5*
Adrenal gland: hypertrophy of Zona fasciculata	1	1	0	8**
Liver: decreased hepatocytic glycogen	1	0	1	8**

*Significantly different from control, p<0.05 ** Significantly different from control, p<0.01

RAC conclusion

RAC concludes that significantly lower absolute weights of reproductive organs were observed among BPAF-treated males. Effects observed on testis and oestrous cycle further indicate endocrine-mediated mechanisms underlying the toxicity of BPAF. Decreased weight of seminal vesicles and ventral prostate in rats is a relatively sensitive indicator of reduced androgen status, which is also supported by the observed Leydig cell atrophy in treated males. No change in female reproductive organs was detected, despite irregularities in oestrous cycle (in line with the OECD TG 422 results), suggesting a potentially weak effect on the female reproductive tract. It is, however, noted that dose levels were rather moderate in this study (under the conditions of the OECD TG 422 described above, animals tolerated longer and higher dosing), and it is unclear whether the effects would have been more pronounced, if the top dose tested had been higher.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
 BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
 HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Mechanistic and non-guideline studies

The DS briefly summarised a range of mechanistic studies in the CLH report. These comprised Level 3 Endocrine Disruptor (ED) assays (Uterotrophic and Hershberger assay) and a range of non-guideline studies (*in vivo* and *in vitro*) all performed with BPAF.

Uterotrophic assay and a Hershberger assay

The assays were conducted according to GLP with BPAF (98.8% purity). The DS reported Klimisch score 3 with reference to the registration dossier, however the registrant assigned them Klimisch 1 as the studies were conducted according to OECD TG 440 and 441, without deviations. Yamasaki *et al.* (2003) studied oestrogenic and androgenic effects of BPAF orally given on 3 consecutive days to 19-day-old rats in the Uterotrophic assay, at doses of 0, 8, 40 and 100 mg/kg bw/d, and for 10 consecutive days in the Hershberger assay at doses of 0, 50, 200 and 600 mg/kg bw/d via oral gavage. BPAF was tested **positive in the Uterotrophic assay** (dose-response), with significantly increased uterine blotted weight at all doses tested, suggesting oestrogenic agonistic properties of BPAF. In addition, watery uterine contents were detected in the high dose group (100 mg/kg bw/d). No significant differences in body weights were seen among treated animals, compared to controls.

Table: Results from the Uterotrophic assay, Yamasaki *et al.*, 2003

Dose levels (mg/kg bw/d)	0	8	40	100
Body weight (g)	56.1 ± 4.3	55.0 ± 4.5	56.6 ± 4.0	54.7 ± 4.2
Uterus blotted weight, absolute (mg)	28.6 ± 4.9	47.2** ± 9.9	65.9** ± 9.8	96.4** ± 9.0
Uterus blotted weight, relative (mg/100 g)	50.9 ± 7.4	85.1** ± 11.9	116.0** ± 11.7	177.2** ± 22.2

** Significantly different from control at p<0.01.

In the Hershberger assay, the relative glans penis weight increased significantly in rats given 600 mg/kg bw/ d of BPAF. However, there were signs of general toxicity at the mid and high dose, which included significantly decreased body weight gain and decreased spontaneous locomotion (no further details available). In addition, the control values for this organ varied considerably, and according to the authors, an androgen agonistic property could not reliably be determined in this study.

Subacute in vivo study

In a non-guideline 14-day *in vivo* study (Feng *et al.*, 2012), adult SD rats (8 males/group) were dosed with BPAF at 0, 2, 10, 50 and 200 mg/kg bw/d. Key finding included decreased total serum cholesterol at doses of 50 and 200 mg/kg bw/d. Moreover, concentrations of BPAF increased dose-dependently in the testes, while **testosterone in serum decreased** significantly in the high dose group. Levels of luteinising hormone and follicle-stimulating hormone increased. Testicular mRNA levels of Inhibin B, oestrogen receptor and luteinising hormone receptor decreased in high dose animals. The NOAEL for BPAF for male SD rats was <10 mg/kg bw/d.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Other mechanistic studies

Several mechanistic studies on the effects of BPAF in zebrafish, and *in vitro*, are available.

Results consistently indicate oestrogenic and anti-androgenic effects of BPAF (decreased testosterone in male fish, increased oestradiol levels and upregulated vitellogenin in males and females), mechanisms of relevance for the effects seen on fertility *in vivo* (Shi *et al.*, 2015, Yang *et al.*, 2016). In addition, some studies are indicative of endocrine disruption of the thyroid (Kwon *et al.*, 2016, Tang *et al.*, 2015).

In vitro studies

Several *in vitro* studies show **oestrogen receptor binding activity**, including binding of BPAF to G protein-coupled oestrogen receptor in human breast cancer cells (Cao *et al.*, 2017), binding and activation of oestrogen receptors in HeLa cells (3-fold stronger binding to ER β than ER α ; fully activated ER α , but being almost completely inactive for ER β) (Matsushima *et al.*, 2010), ER α -agonistic behaviour at lower concentrations (nanomolar) and anti-oestrogenic action via the induction of ER β at higher concentrations in human breast cancer cells (Okazaki *et al.*, 2017). BPAF was the most potent BPA analogue, followed by BPB, BPZ, BPA, BPAP and BPS in stimulating cell growth in an ER-mediated cell proliferation assay and inducing oestrogen response element-mediated transcription in a luciferase assay (Mesnage *et al.*, 2017). BPAF altered steroidogenesis in H295R cells inducing progesterone levels and reducing testosterone levels (Feng *et al.*, 2014), exhibited agonistic oestrogenic activity in the MCF-7 Oestrogen Luciferase Reporter Assay and inhibitory effects on the androgenic activity of 5 α -dihydrotestosterone in the mouse fibroblast cell line NIH3T3 (Kitamura *et al.*, 2005). Moreover, BPAF elicited oestrogenic and thyroidal effects in two-hybrid yeast bioassay (Lei *et al.*, 2017) and agonistic oestrogenic and AR-antagonist activity in a luciferase reporter assay using African green monkey kidney cells (Teng *et al.*, 2013).

Further considerations: structural similarity to BPA and BPS

The structural similarity of BPAF to BPA was highlighted by the DS. Bisphenol A has a harmonised classification as Repr. 1B (H360F) and affects the reproductive system similarly. Fertility assessment concluded significantly decreased number in litters/pair in two- and multigeneration studies. Although data are mainly from animals exposed *in utero* and/or postnatally, irregularities in the oestrus cycle, ovarian cysts and decreased numbers of implantation sites were also observed for BPA. In males, exposure to BPA decreased the levels of testosterone, sperm production and weights of reproductive organs.

Disruption of oestrogenic signalling was considered to be the main mode of action for the effects of BPA on fertility. The hormonal systems are well conserved between mammalian species, and the effects that have been observed in rodents were therefore also considered relevant for humans (ECHA RAC, 2014).

RAC recently assessed another structural analogue of BPAF, BPS. Bisphenol S consistently and severely disturbed reproductive parameters and RAC classified BPS as Repr. 1B; H360F, based on adverse effects on fertility, reproduction and pregnancy outcome, including a decreased number of implantation sites, reduction of fertility index down to 60%, and prolongation and irregular oestrus cycle at comparable dosing with 300 mg/kg bw/d (ECHA RAC, 2020).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

RAC conclusion

In line with the DS, and in a weight of evidence approach, RAC concludes that the available data provide clear evidence of adverse effects on sexual function and fertility, especially with regards to the fertility index from doses of 30 mg/kg bw/d and above. Changes in male reproductive organ weight, size and histopathology are indicative of an (anti-androgenic) endocrine mechanism. Based on the available data oestrogenic or anti-androgenic mechanism are thought to play a dominant role *in vivo*. As there is no mechanistic information indicating that the observed effects are not relevant for humans, adverse effects on sexual function and fertility are relevant for classification. In fact, oestrogen receptor binding activity of BPAF has been demonstrated in human derived cell lines. Data on BPA and BPS are considered as supportive for the classification proposal for BPAF on this endpoint.

Effects on male mammary glands (transformation to tubuloalveolar pattern observed with higher incidence and severity in male rats at 300 mg/kg bw/d compared to controls in an OECD TG 422 study) may indicate the presence of additional endocrine mechanisms/targets. While this sign of increased cellular growth could be interpreted as 'feminisation', the atrophy of the mammary gland observed in male rats at 100 mg/kg bw/d BPAF in the 28-day study indicates a suppressive effect on the mammary gland. Although the BPA data on the mammary gland effects in offspring following *in utero*/perinatal exposures (which indicate that the mammary gland in female offspring is a target organ) are not directly comparable to the data for BPAF (only data on oral route and on effects in young adult/parental animals available), BPAF-related effects on the mammary gland were generally only seen in male (young adult) rats, but not in female (young adult) rats.

In male rats, mammary gland effects were of depressive nature in treated young adults (as a result of the 28-day treatment with 100 mg/kg bw/d of BPAF), while increased proliferation was seen at 300 mg/kg bw/d after a longer treatment period (42 days, with and without recovery, in the TG 422 study).

Due to the uncertainty, as the database is limited (based on the TG 407 and TG 422 studies only) and the inconsistency of the nature of effects (atrophy versus increased tubuloalveolar differentiation), no robust conclusion on the potential for 'feminisation' of the mammary glands of male animals can be drawn at this time for the endpoint fertility.

Adverse effects on development of the offspring

The DS evaluated adverse effects on development of BDDP-BPAF mainly based on a screening test with BPAF in rats performed according to OECD TG 422, as well as on a few non-guideline studies with BPAF, which were identified during a literature search.

RAC takes note of the upcoming Modified One-Generation (MOG) study of the National Toxicology Program (NIEHS) with BPAF from which tabled summary results have recently been published², but for which a study report is not yet published³.

² https://tools.niehs.nih.gov/cebs3/views/?action=main.dataReview&bin_id=14942

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

OECD TG 422

In the OECD TG 422 study (described in more detail under Adverse effects on sexual function and fertility), no pregnant females and, thus, no pups were produced at the high dose of 300 mg/kg bw/d. Therefore, developmental effects at this dose could not be assessed in this study.

At the lower doses, no significant effects on *in utero* treated offspring were observed. Post-implantation loss was higher in the mid dose group, but differences were not statistically significant (10%, 8% and 23% for controls, low and mid dose groups, respectively).

Viability index and percentages of live births were not affected. There were further no differences in sex ratio and body weights of offspring between treated animals and controls. No evident effects from BPAF treatment were noted during necropsy. The DS noted that pups were examined only until PND 5, although examination and termination at PND 13 is indicated in the current OECD TG 422 (adopted in 2016).

Further data

There are a few recent non-guideline studies that report effects on offspring treated during the foetal period.

Tucker *et al.* (2018) investigated the effects of BPAF on development and long-term health of the mammary gland in female CD-1 mice. Pregnant dams were given 0.05 mg/kg bw/d (n=10), 0.5 mg/kg bw/d (n=11) or 5 mg/kg bw/d (n=11) of BPAF, via oral gavage, twice daily from GD 10.5 (prior to formation of the rudimental mammary epithelial bud) until GD 17.5. Female offspring were followed for up to 16 months. The reported effects included, among others, accelerated mammary gland development of female offspring treated *in utero* and mammary gland lesions in the female offspring of treated dams. The DS indicated that these effects were dose-dependent. On closer inspection, a clear dose-dependency may not be inferred for the histopathological lesions, but significant effects are reported for the high dose, including mammary gland cysts (3/22 [14%], 0% for other groups), and mixed cell inflammation found at low incidences in all treatment groups (1/12 [8%], 1/14 [7%] and 2/18 [11%] in controls, low dose and mid dose groups, respectively) in contrast to the high dose group where 8/22 (36%) females exhibited this effect. Furthermore, lobuloalveolar hyperplasia in mammary glands was observed at mid and high dose (1/18 [6%] and 5/22 [23%], respectively, significant trend $p < 0.01$), and squamous metaplasia was reported with increasing incidences (0/13 [0%], 1/14 [7%], 2/18 [11%], 7/22 [32%], for control, low, mid and high dose, respectively, significant trend $p < 0.01$). The assessment of mammary gland development showed significant results between PND 20 and 35, including greater longitudinal growth and branching density, higher terminal endbuds (TEB) counts and more TEB/mm², indicating a potential treatment-related accelerated growth.

In another study (Li *et al.*, 2006), transfer of BPAF via breast milk during lactation and impact of BPAF treatment on testosterone levels in serum and androgen receptor levels in

³ https://ntp.niehs.nih.gov/whatwestudy/testpgm/status/ts-08002.html?utm_source=direct&utm_medium=prod&utm_campaign=ntpgolinks&utm_term=ts-08002

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

testes of male offspring of treated dams were reported. Furthermore, increased anxiety and depressive-like behaviours in male adolescent offspring due to foetal BPAF treatment were reported in a further study. The DS noted that these parameters were not assessed in the OECD TG 422 study.

Further considerations: structural similarity to BPA

There are a number of studies that reported increased cellular growth in the mammary gland of female animals (rats and mice), at several sites (ductal, alveolar buds and/or terminal buds, not all consistent), following *in utero*, perinatal and/or postnatal exposure to BPA. A number of them showed effects only at low doses without effects at higher doses and some inconsistencies in the effect patterns (for review see Table in Mandrup *et al.*, 2016). Few studies observed mammary gland effects in male offspring.

The observation of low dose effects of BPA and the transient nature of findings was confirmed by the more recent study of Mandrup *et al.* (2016). Perinatal exposure (GD 7-21) of BPA to rats induced mammary gland longitudinal growth in male offspring (only) on post-natal day (PND) 22 at oral doses of 0.025 mg/kg bw/d of BPA, and ductal hyperplasia in adult females at 0.25 mg/kg bw/d at PND 400, but not at PND 100 (Mandrups *et al.*, 2016). These effects on male and female rats were not seen at higher doses, and effects in male rats were not seen at PND 100 or 400. Although a tubuloalveolar pattern with lumens was not present in male rats, authors considered the changes as an early shift toward a female-like morphology.

(A more detailed review may be considered in a later CLH dossier on the developmental toxicity, if justified by data of the new NTP study or other data.)

RAC conclusion

RAC concludes that a robust *in vivo* developmental toxicity study is lacking in the CLH report, thus, hampering full assessment of developmental toxicity of BPAF. RAC, however, also notes that the (raw) data of the modified one generation study highlighted by the DS are already available, while a summary report is still pending. This additional data might provide sufficient information for deciding on whether classification of BPAF, and thus BDDP-BPAF for developmental toxicity is warranted.

Adverse effects on or via lactation

The DS evaluated effects of BDDP-BPAF on or via lactation based on the OECD TG 422 study and a non-guideline cross-fostering study with BPAF (Li *et al.*, 2016). Results from the above described screening study are not indicative of any effects of BPAF on or via lactation. However, pups were followed until PND 5 only. The cross-fostering study was not considered robust enough by the DS to be used as basis for classification due to poor reporting (the registrant(s) assigned Klimisch 4).

RAC conclusion

RAC agrees that it is not possible to draw conclusions on adverse effects of BPAF, and thus BDDP-BPAF, on or via lactation based on the available information.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Comparison with the CLP criteria

Repr. 1A; H360 (known human reproductive toxicant): The classification of a substance in Category 1A is largely based on evidence from humans.

Repr. 1B; H360 (presumed human reproductive toxicant): The classification of a substance in Category 1B is largely based on data from animal studies. Such data shall provide clear evidence of an adverse effect on sexual function and fertility or on development in the absence of other toxic effects, or if occurring together with other toxic effects the adverse effect on reproduction is considered not to be a secondary non-specific consequence of other toxic effects.

Repr. 2; H361 (suspected human reproductive toxicant): Substances are classified in Category 2 for reproductive toxicity when there is some evidence from humans or experimental animals, possibly supplemented with other information, of an adverse effect on sexual function and fertility, or on development, and where the evidence is not sufficiently convincing to place the substance in Category 1. If deficiencies in the study make the quality of evidence less convincing, Category 2 could be the more appropriate classification. Such effects shall have been observed in the absence of other toxic effects, or if occurring together with other toxic effects the adverse effect on reproduction is considered not to be a secondary non-specific consequence of the other toxic effects.

With respect to adverse effects on sexual function and fertility, RAC concludes that BPAF has a clear and adverse impact on pregnancy outcomes in rats with a dose-dependent decrease in fertility index and no pregnancies achieved at the top dose of 300 mg/kg bw/d. RAC highlights the steep dose-response curve, seen at doses at which general toxicity was not marked and not severe enough to explain the observed effects on fertility. Thus, these effects are considered a direct toxic effect and not of secondary non-specific nature. Further experimental observations support this conclusion, as disturbance of oestrus cycle, adverse effects on testis, a positive outcome of the Uterotrophic assay, as well as various mechanistic *in vitro* studies on oestrogenicity suggest an endocrine mediated mechanism of action for the main constituent of BDDP-BPAF, i.e. BPAF.

Classification in Category 1A is not appropriate as no relevant human data is available supporting harmonised classification in this category. Classification in Category 2 is not appropriate as the evidence for adverse effects on sexual function and fertility is considered clear evidence. This conclusion is in line with the previous RAC assessments of the two structurally very similar chemicals, BPA and BPS, which both were concluded to elicit similar but not as potent effects on pregnancy outcomes and fertility index as BPAF via an oestrogenic main mode of action.

RAC concludes that classification for adverse effect on sexual function and fertility of BDDP-BPAF as Repr. 1B; H360F, is justified.

With regards to developmental toxicity, the assessment of adverse effects on offspring development is essentially hampered, as no robust *in vivo* prenatal developmental toxicity study is available in the CLH dossier. In the OECD TG 422 study no effects on *in utero* treated offspring were noted that would warrant classification, and at the high dose no pregnancy was achieved at all. However, RAC notes that an OECD TG 422 does not

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

provide adequate information on developmental toxicity, e.g. compared to an OECD TG 414.

The effects on female mice mammary gland development and male offspring testosterone levels and adolescent behaviours reported in the supplementary studies retrieved from the public literature are considered insufficiently robust for classification, although indicating a concern. RAC notes that the (raw) data from the Modified One Generation study conducted by the U.S. NTP are publicly available already, while a summary report is still pending. This data was therefore not considered in the current opinion. Hence, **RAC concludes that classification of BDDP-BPAF for adverse effects on development of the offspring is not warranted due to inconclusive data.**

In line with the DS, RAC considers that is not possible to draw conclusions on adverse effects on or via lactation based on the limited information available. **No classification is proposed for adverse effects on or via lactation due to insufficient data.**

Supplemental information - In depth analyses by RAC

Toxicokinetics and bioavailability of BPAF was investigated in rodents after oral and i.v. dosing with single and repeated doses (non-guideline *in vivo* experimental studies). No guideline-conform toxicokinetics studies with BPAF are available.

Single dosing

Single dosing studies were conducted rather recently by the U.S. NTP.

Waidyanatha (2015) assessed clearance and metabolism of BPAF (purity: 97%) in rodents following oral administration of 3.4, 34 or 340 mg/kg [(14)C]BPAF. [(14)C]BPAF-associated radioactivity was excreted primarily in faeces by 72 h after oral administration to rats (65-80%) and mice (63-72%). Females excreted [(14)C]BPAF to a higher extent in urine than males. Metabolites identified in bile were BPAF-glucuronide, -diglucuronide, -glucuronide sulfate and -sulfate, while >94% of faecal radioactivity was present as BPAF, suggesting extensive deconjugation in the intestine.

Waidyanatha (2019) assessed toxicokinetics and bioavailability of BPAF (purity: 99%) in male and female Harlan Sprague Dawley rats and B6C3F1/N mice following a single gavage administration of 34, 110, or 340 mg/kg bw/d. Plasma concentrations were measured 0, 5, 15, 30 min, 1, 2, 4, 8, 12, 24, 32 and 48 h post-exposure. BPAF was rapidly absorbed in rats with the maximum plasma concentration (C_{max}) of free BPAF reached at ≤ 2.20 h. BPAF was cleared rapidly with a plasma elimination half-life of ≤ 3.35 h. C_{max} of the sum of free and conjugated BPAF was reached ≤ 1.07 h in rats with both C_{max} (≥ 27 -fold) and $AUC_{0-\infty}$ (≥ 52 -fold) being much higher than corresponding free values, demonstrating rapid and extensive conjugation of BPAF following oral administration. In mice after oral administration of 34 mg/kg, C_{max} of free BPAF was reached more rapidly (C_{max} : ≤ 0.455 h) than in rats and BPAF was cleared more rapidly, with an elimination half-life of ≤ 4.22 h. The authors used $AUC_{0-\infty}$ of free BPAF following gavage and IV administration (Bioavailability (%F) as $AUC/Dose$ (oral) \div $AUC/Dose$ (i.v.) $\times 100$) to estimate oral bioavailability and concluded that the bioavailability of free BPAF in rats was $\sim 1\%$ with no apparent dose-related effect. Bioavailability of free BPAF in mice was slightly higher than in rats (males $\sim 6\%$, females $\sim 3\%$). Overall, BPAF was rapidly

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

and extensively conjugated likely due to extensive first pass conjugation in the intestine and the liver, with rapid elimination from plasma or serum.

Repeated dosing

Yang *et al.* (2012) analysed traces in various tissues and excreta of BPAF (purity: 98%) given orally at doses of 10 mg/kg bw to 4 male Sprague Dawley rats, daily for 2 consecutive weeks. Urine and faeces samples were collected, as well as serum and tissues, including kidneys, liver, testis, adipose and muscle. High levels of BPAF were detected in liver, kidney and serum. BPAF was also detected in other organs, such as testes. The liver seemed to be the main organ responsible for metabolism. The highest level of BPAF was found in faeces (in unconjugated form).

In a study by Li *et al.* (2013), BPAF (purity: 98%) was given orally (200 mg/kg bw/d) to male Sprague-Dawley rats, daily for 2 consecutive weeks (no. of animals not reported). For serum analysis animals were given a single oral dose of 20 mg/kg or 100 mg/kg (n=3). The study identified four metabolites including BPAF-diglucuronide, -glucuronide (BPAF-G), -glucuronide dehydrated and -sulphate in the urine of the rats.

BPAF-glucuronide was the major metabolite formed *in vivo*. Glucuronidation was a rapid and efficient pathway for biotransformation of BPAF. The peak of BPAF-glucuronide in plasma was observed 30 minutes after treatment, followed by a rapid decline during the next 3 hours, indicating a fast clearance in rats. The peak of BPAF was observed at 1 hour, and BPAF was completely eliminated after 48 hours. The three other metabolites were not found in plasma.

RAC takes note of a recent publication by NTP, not part of the CLH report (Waidyanatha, 2020), assessing comparative toxicokinetic of BPAF (338, 1125, and 3750 ppm) and BPS following exposure via feed for 7 days in male rats and mice. The study confirms glucuronidation to be a major metabolic pathway *in vivo*. Elimination half-lives for free substance (4.41-10.4 h) were comparable between species and analogues. In rats, the exposure concentration-normalised maximum concentration [C_{max}/D (ng/mL)/(ppm)] and area under the concentration time curve [AUC/D (h × ng/mL)/(ppm)] was higher for free BPS (C_{max}/D : 0.476-1.02; AUC/D: 3.58-8.26) than for free BPAF (C_{max}/D : 0.017-0.037; AUC/D:0.196-0.436). Bisphenol S and BPAF were highly conjugated; AUC values for total BPS and total BPAF were higher than corresponding free values (BPS: rats ≥18-fold, mice ≥17-fold; BPAF: rats ≥127-fold, mice ≥16-fold). Data demonstrated that there are analogue and species differences in the kinetics of BPS and BPAF.

The authors estimated the actual average daily intake of BPAF based on feed consumption data was 23.4, 70.5 and 193.0 mg/kg bw/d for male rats and 69.4, 236.0 and 1590 mg/kg bw/d for male mice. For BPS, the estimated daily doses were 23.0, 76.8 and 298.0 mg/kg bw/d for male rats and 131.4, 428.0 and 1176.0 mg/kg bw/d for male mice. Thus, the doses administered to rats were similar to the low and mid dose treatment group in the OECD TG 422 study with BPAF (30, 100, 300 mg/kg bw/d for low, mid and high dose, respectively).

10.11 Specific target organ toxicity-single exposure

Not evaluated in this CLH-proposal.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

10.12 Specific target organ toxicity-repeated exposure

Not evaluated in this CLH-proposal.

10.13 Aspiration hazard

Not evaluated in this CLH-proposal.

11 EVALUATION OF ENVIRONMENTAL HAZARDS

Not evaluated in this CLH-proposal.

12 EVALUATION OF ADDITIONAL HAZARDS

Not evaluated in this CLH-proposal.

13 ADDITIONAL LABELLING

Not relevant.

14 REFERENCES

Cao et al. Bisphenol AF and bisphenol B exert higher estrogenic effects than bisphenol A via G protein-coupled estrogen receptor pathway. *Environ Sci Technol* 51 (2017) 11423–11430.

Ding et al. Bisphenol AF negatively affects oocyte maturation of mouse in vitro through increasing oxidative stress and DNA damage. *Chemico-Biological Interactions* 278 (2017) 222–229.

ECHA dissemination (2019). Available at: <https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/23236>

Feng et al. Bisphenol AF may cause testosterone reduction by directly affecting testis function in adult male rats. *Toxicology letters* 211 (2012) 201-209.

Feng et al. Effects of bisphenol analogues on steroidogenic gene expression and hormone synthesis in H295R cells. *Chemosphere* 147 (2016) 9e19.

Fic et al. Estrogenic and androgenic activities of TBBA and TBMEPH, metabolites of novel brominated flame retardants, and selected bisphenols, using the XenoScreen XL YES/YAS assay. *Chemosphere* 112 (2014) 362-369.

Furr et al. A short-term in vivo screen using fetal testosterone production, a key event in the phthalate adverse outcome pathway, to predict disruption of sexual differentiation. *Toxicol Sci* 140(2) (2014) 403-424.

Gong et al. Effects of maternal exposure to bisphenol AF on emotional behaviors in adolescent mice offspring. *Chemosphere* 187 (2017) 140e146.

Jin et al. Occurrence and Partitioning of Bisphenol Analogues in Adults' Blood from China. *Environ Sci Technol*. 52(2) (2018) 812-820.

Kitamura et al. Comparative Study of the Endocrine-Disrupting Activity of Bisphenol A and 19 Related Compounds. *Toxicological Sciences* 84(2) (2005) 249–259.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Kwon et al. Thyroid endocrine disruption in male zebrafish following exposure to binary mixture of bisphenol AF and sulfamethoxazole. *Environmental Toxicology and Pharmacology* 48 (2016) 168–174.

Larsson et al. Phthalates, non-phthalate plasticizers and bisphenols in Swedish preschool dust in relation to children's exposure. *Environment International* 102 (2017) 114–124.

Lee et al. Neurotoxic effects of bisphenol AF on calcium-induced ROS and MAPKs. *Neurotox Res* 23 (2013) 249–259.

Lei et al. In vitro profiling of toxicity and endocrine disrupting effects of bisphenol analogues by employing MCF-7 cells and two-hybrid yeast bioassay. *Environ Toxicol* 32(1) (2017) 278–289.

Lei et al. Low-concentration BPAF- and BPF-induced cell biological effects are mediated by ROS in MCF-7 breast cancer cells. *Environ Sci Pollut Res Int* 25(4) (2018) 3200–3208.

Li et al. Gestational and lactational exposure to bisphenol AF in maternal rats increases testosterone levels in 23-day-old male offspring. *Chemosphere* 163 (2016) 552–651.

Li et al. Biotransformation of Bisphenol AF to its major glucuronide metabolite reduces estrogenic activity. *PLoS ONE* 8(12) (2013) e83170.

Liao and Kannan. Concentrations and profiles of bisphenol A and other bisphenol analogues in foodstuffs from the United States and their implications for human exposure. *J Agric Food Chem* 61(19) (2013) 4655–4662.

Matsushima et al. Bisphenol AF Is a Full Agonist for the Estrogen Receptor ER α but a Highly Specific Antagonist for ER β . *Environ Health Perspect* 118 (2010) 1267–1272.

Mesnager et al. Transcriptome profiling reveals bisphenol A alternatives activate estrogen receptor alpha in human breast cancer cells. *Toxicol Sci* 158 (2) (2017) 431–443.

Mokra et al. Evaluation of DNA-damaging potential of bisphenol A and its selected analogs in human peripheral blood mononuclear cells (in vitro study). *Food Chem Toxicol* 100 (2017) 62–69.

Moreman et al. Acute toxicity, teratogenic, and estrogenic effects of bisphenol A and its alternative replacements bisphenol S, Bisphenol F, and Bisphenol AF in zebrafish embryo-larvae. *Environ Sci Technol* 51 (2017) 12796–12805.

National Toxicology Program (NTP), Chemical Information Profile for Bisphenol AF Nomination summary (2008).

Niu et al. Highly Sensitive and High-Throughput Method for the Analysis of Bisphenol Analogues and Their Halogenated Derivatives in Breast Milk. *J. Agric. Food Chem* 65 (2017) 10452–10463.

Okazaki et al. Bisphenol AF as an Inducer of Estrogen Receptor β (ER β): Evidence for Anti-estrogenic Effects at Higher Concentrations in Human Breast Cancer Cells. *Biol. Pharm. Bull.* 40 (2017) 1909–1916.

Shi et al. Long-term effects of Bisphenol AF (BPAF) on hormonal balance and genes of hypothalamus-pituitary-gonad axis and liver of zebrafish (*Danio rerio*), and the impact on offspring. *Chemosphere* 128 (2015) 252–257.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON FOR
BENZYL(DIETHYLAMINO)DIPHENYLPHOSPHONIUM 4-[1,1,1,3,3,3-HEXAFLUORO-2-(4-
HYDROXYPHENYL)PROPAN-2-YL]PHENOLATE

Study report 2011, 4,4'-(1,1,1,3,3,3-hexafluoropropane-2,2-diyl)diphenol: oral (gavage) combined repeated dose toxicity study with reproduction/developmental toxicity screening test in the rat (OECD 422 1996 with recovery groups) (2011).

Tang et al. Thyroid Disruption in Zebrafish Larvae by Short-Term Exposure to Bisphenol AF. *Int. J. Environ. Res. Public Health* 12 (2015) 13069-13084.

Teng et al. Bisphenol A affects androgen receptor function via multiple Mechanisms. *Chem Biol Interact* 203(3) (2013) 556-564.

Tucker et al. Evaluation of prenatal exposure to bisphenol analogues on development and long-term health of the mammary gland in female mice. *EHP* 126(8) (2018) 087003.

Umano et al. Endocrine-mediated effects of 4,4'-(hexafluoroisopropylidene)diphenol in SD rats, based on a subacute oral toxicity study. *Arch Toxicol* 86(1) (2012) 151-157.

Waidyanatha et al. Disposition of bisphenol AF, a bisphenol A analogue, in hepatocytes in vitro and in male and female Harlan Sprague-Dawley rats and B6C3F1/N mice following oral and intravenous administration. *Xenobiotica* 45(9) (2015) 811-819.

Waidyanatha et al. Toxicokinetics and bioavailability of bisphenol AF following oral administration in rodents: A dose, species, and sex comparison. *Toxicology and Applied Pharmacology* 373 (2019) 39-47.

Yamasaki et al. Immature rat uterotrophic assay of 18 chemicals and Hershberger assay of 30 chemicals. *Toxicology* 183 (2003) 93-115.

Yang et al. Urinary levels of bisphenol analogues in residents living near a manufacturing plant in south China. *Chemosphere* 112 (2014) 481-486.

Yang et al. Exposure to Bisphenol AF Disrupts Sex Hormone Levels and Vitellogenin Expression in Zebrafish. *Environ Toxicol* 31 (2016) 285-294.

Yang et al. Determination of bisphenol AF (BPAF) in tissues, serum, urine and feces of orally dosed rats by ultra-high-pressure liquid chromatography-electrospray tandem mass spectrometry. *Journal of Chromatography B* 901 (2012) 93-97.

Additional references

Mandrup, K. *et al.* (2016): Low-dose effects of bisphenol A on mammary gland development in rats. *Andrology*. 2016 Mar 1; 673-683.

Waidyanatha, S. *et al.* (2020): Comparative toxicokinetics of bisphenol S and bisphenol AF in male rats and mice following repeated exposure via feed. *Xenobiotica*. 2020 Oct 6;1-12.